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ABSTRACT 
 
Human Immunodeficiency Virus type 1 (HIV-1) is the causal agent of AIDS, and 
currently infects 33.3 million individuals worldwide. The gradual depletion of CD4+ T 
lymphocytes is a characteristic feature of a progressive HIV-1 infection. During HIV-1 
infection the number of infected CD4+ T lymphocytes is fewer than the number of 
CD4+ T lymphocytes that are depleted, therefore suggesting a role for HIV-mediated 
apoptosis of uninfected bystander CD4+ T lymphocytes. Apoptosis, also known as 
programmed cell death, is a highly regulated, normal physiological process that 
results in the disposal of unwanted or corrupted cells such as virally infected cells.  
Several HIV-1 proteins are involved in HIV-1-mediated apoptosis, of which the 
envelope (Env) glycoprotein gp120 subunit is the most effective. However, the true 
mechanism of gp120-mediated apoptosis of uninfected CD4+ T lymphocytes is not 
fully understood and remains controversial. Furthermore, research focusing on HIV-1 
subtype C Env-mediated apoptosis is limited. This study compared the ability of 
CCR5-utilizing soluble monomeric HIV-1 subtype C gp120 (gp120ZM651), monomeric 
HIV-1 subtype B gp120 (gp120BaL) and trimeric/oligomeric HIV-1 subtype C gp140 
(gp140AncC) to induce apoptosis of uninfected Jurkat T lymphocytes and activated 
CD4+ T lymphocytes via CD4 and CD4/CCR5 signalling, respectively. All three Env 
glycoproteins were expressed in HEK 293T cells, purified by lectin affinity 
chromatography and characterized by assessing their binding capabilities to 
monoclonal antibodies IgGb12, 17b (in the presence and absence of soluble CD4) 
and 2G12. Purified recombinant gp120BaL, gp120ZM651 and gp140AncC were found to 
 v 
be functional and conformationally intact and subsequently added in different 
concentrations to uninfected Jurkat T lymphocytes and activated CD4+ T 
lymphocytes.  Apoptosis was detected by flow cytometry using Annexin V/7-AAD 
staining for up to 48 hours post treatment, and further confirmed by TUNEL analysis 
at 65 hours post treatment. Recombinant gp120BaL, gp120ZM651 and gp140AncC 
induced low levels of apoptosis in the Jurkat T lymphocytes (6.1%, 5.0% and 6.8%, 
respectively) and higher levels of apoptosis in the activated CD4+ T lymphocytes 
(13.3%, 15.6% and 11.5%, respectively) via TUNEL analysis of chromosomal DNA 
fragmentation. Moreover, comparable levels of apoptosis were observed between the 
monomeric gp120 and trimeric/oligomeric gp140 forms in both cell types. 
Interestingly, the subtype C gp140AncC induced higher levels of apoptosis than 
subtype C gp120ZM651 and subtype B gp120BaL in activated CD4+ T lymphocytes 
during the Annexin V/7-AAD analysis while the subtype C gp120ZM651 induced higher 
levels of apoptosis than subtype C gp140AncC and subtype B gp120BaL in activated 
CD4+ T lymphocytes during the TUNEL analysis. Overall, these results suggest that 
soluble gp120 is able to mediate low levels of apoptosis via CD4 signalling only in 
Jurkat T lymphocytes, and these levels are enhanced in activated CD4+ T 
lymphocytes, possibly due to engagement of gp120 with CD4 and the CCR5 co-
receptor on the surface of the target cell. 
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CHAPTER 1: INTRODUCTION 
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1.1 Human Immunodeficiency Virus and AIDS 
 
Acquired Immune Deficiency Syndrome (AIDS) was given its name in 1982 by the 
United States Centre for Disease Control and Prevention (CDC) [1]. It is commonly 
defined by the disruption and loss of cellular immune responses due to a decline in 
CD4+ T helper lymphocytes and the occurrence of opportunistic infections such as 
candidiasis and pneumonia [2-4]. The initial clinical encounter of AIDS was reported 
in the United States of America in 1981 after previously healthy young homosexual 
men began to develop unusual diseases such as Kaposi’s sarcoma and pneumonia 
[2, 3]. Eventually, AIDS became apparent in the heterosexual population resulting in a 
global epidemic. 
 
In 1983, Luc Montagnier and his research team reported the discovery of a new 
retrovirus as the cause of AIDS and named it lymphadenopathy-associated virus 
(LAV) [5]. This discovery was confirmed by Robert Gallo and his research team who 
had renamed the virus as the human T-cell lymphotropic virus type 3 (HTLV-III) [5, 6]. 
In 1986, after reaching a consensus, the retrovirus was finally renamed Human 
Immunodeficiency Virus (HIV) [7].  
 
HIV destroys and disables the immune system by establishing prolonged infections 
within major immune defence cells such as the CD4+ T helper lymphocytes, 
macrophages and dendritic cells, resulting in the production of weak neutralizing 
 3 
antibodies and antigen specific cellular immune responses involving cytotoxic CD8+ T 
lymphocytes and CD4+ helper T lymphocytes [4]. Transmission of infection occurs by 
bodily fluids (semen, blood and breast milk) that contain virus particles and this is 
commonly facilitated by unprotected sexual intercourse, use of contaminated needles 
and from mother-to-child by breast feeding or intra-, peri- or post partum [8] [1]. 
  
1.2 HIV subtypes and groups 
 
HIV shows incredible genetic diversity due to its high mutation rate and this has 
contributed to the development of multiple variants or strains. HIV type 1 (HIV-1) and 
HIV type 2 (HIV-2) are the two main types of HIV that originated in central West Africa 
by zoonotic transmission of Simian Immunodeficiency Virus (SIV) from the 
chimpanzee (Pan troglodytes) [9] and sooty mangabey monkeys (Cercoebus atys) 
[10], respectively. HIV-1 is the most virulent and predominant type globally while HIV-
2,  with partial homology to HIV-1, is less virulent and commonly found in central 
West Africa [10].  
 
Owing to the emergence of multiple and genetically different strains, HIV-1 was 
classified into  3 groups: M (major), N (non-M/non-O) and O (outlier) based on the 
envelope sequences [11]. Groups N and O isolates are quite rare, while Group M 
isolates constitute the cause of the global epidemic. More recently, Group P has been 
introduced into the classification of HIV-1, containing an HIV-1 isolate derived from 
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gorilla SIV [12]. Group M is sub-divided into 9 genetically different subtypes: A-D, F, 
G, J and K based on the entire genome [11]. The subtypes show up to 30% and 15% 
diversity in their envelope (Env) glycoprotein and gag amino acid sequences, 
respectively [11]. The most prevalent subtypes include subtypes A, B, C and D. 
Subtype B is found mainly in North America, North Africa, Asia and west and central 
Europe, while subtypes A, C and D are found mainly in Africa [11]. Different subtypes 
are able to infect a single individual and recombination of their genetic material occurs 
to produce new viruses [13, 14]. If the new viruses are viable, able to survive or be 
transmitted, and are identified in epidemiologically non-related individuals, they are 
known as a circulating recombinant forms (CRFs) [13, 14]. There has been an 
increased incidence of CRFs which now contribute significantly to global HIV 
pandemic [15, 16]. There are currently 49 identified CRFs circulating globally, and this 
number is expected to increase (Los Alamos National Laboratory 
http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). 
 
1.3 What is the significance of the HIV/AIDS epidemic globally and 
in Sub-Saharan Africa? 
 
There are currently 33.3 million individuals worldwide who are living with HIV infection 
[17].  In 2009, up to 1.8 million people died of AIDS and an estimated total of 2.6 
million new infections occurred globally [17]. However, there has been a significant 
reduction in the number of AIDS-related deaths and progress in the prevention of HIV 
 5 
infection, since antiretroviral treatments have become more readily available in less 
developed countries. In 1997, an estimated 3.2 million new infections occurred, while 
in 2009, the number of new infections dropped by 21% [17]. In the same regard, there 
were 2.1 million AIDS–related deaths in 2004 which dropped to 1.8 million in 2009 
[17]. In addition, there has been an estimated 19% decrease in AIDS-related deaths 
among children all over the globe between 2004 and 2009 [17]. Sub-Saharan Africa 
still accounts for 72% (1.3 million adults and children) of the worlds AIDS-related 
deaths and 68% of the total number of people living with HIV globally[17]. HIV 
contributes to the poverty and economic distress that is experienced by Sub-Saharan 
Africa but treatment availability has improved and as a result AIDS-related death 
rates have decreased [17]. Even though the epidemic seems to be stabilizing in 
various countries, it prevails in other countries such as Eastern Europe and Central 
Asia due to increased numbers of new infections [17].  
 
AIDS-induced deaths, the occurrence of opportunistic infections and viral replication 
can be controlled by Highly Active Antiretroviral Therapy (HAART) [18, 19], which is a 
combination of three different drugs that target different stages of the HIV life cycle 
[20]. Most clinically approved drug regimens include drugs that are directed towards 
the 3 viral enzymes, reverse transcriptase (RT), integrase (INT) and protease (PR) as 
well as those targeting viral entry [21, 22]. Owing to the high mutation rate and lack of 
proofreading ability of RT [23], the virus easily develops resistance to many 
antiretroviral drug regimens. For this reason, the discovery or development of a 
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vaccine against HIV and AIDS remains an ongoing struggle. Despite the struggle, 
since 2004, more than 5 million people are now receiving HAART globally [17]. 
 
1.4 The biology of HIV-1 and the structural organization of its 
genome  
 
As shown in Figure 1.1, mature HIV-1 virions are roughly spherical and encapsulated 
by a double layered cholesterol and sphingomyelin-rich phospholipid envelope which 
is obtained from the host cell phospholipid membrane [24-26]. Trimeric Env 
glycoprotein spikes are embedded within the phospholipid envelope, each consisting 
of a surface glycoprotein (gp120) and a transmembrane glycoprotein (gp41) [27]. Two 
identical single plus strands of viral RNA (ssRNA) associated with nucleocapsid 
proteins [28-30], accessory proteins Vpr, Vif and Nef and essential viral enzymes 
such as RT, INT and PR are located within the bullet-shaped capsid core [31-33]. The 
RT has DNA polymerase and RNase H (RH) functions to assist in the conversion of 
ssRNA to double stranded complementary DNA (dsDNA) [34]. The capsid is 
separated from the phospholipid envelope by a protein matrix layer that ensures the 
integrity of the virion [35] (Figure 1.1). 
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Figure1.1: The structure and biology of an HIV particle 
 
The HIV-1 genome contains 9 genes, encoding for structural, accessory and 
regulatory proteins, each holding a unique function [36-41]. Structural proteins are 
encoded by the gag, env and pol genes [38-42]. The gag gene encodes viral capsid 
(p24) and matrix (p17) proteins, all of which are essential for viral assembly [32, 41, 
43-45]. Important viral enzymes: RT, PR and INT are expressed by the gag-pol open 
reading frame, by ribosomal frame shifting [46]. Env encodes the large Env 
glycoprotein precursor gp160, which is cleaved by host cellular proteases to produce 
gp120 and gp41 [41]. Regulatory genes tat and rev encode for proteins that are 
essential for the regulation of viral protein transcription and translation [37, 41, 42].  
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Accessory genes vif, vpr, vpu and nef encode proteins that assist in viral infection and 
protect the virus during its life cycle [37, 41, 42, 47, 48]. 
 
1.5 HIV-1 lifecycle 
 
Viral entry, reverse transcription of viral RNA, integration of the complementary viral 
DNA into the host genome, transcription, translation, viral assembly, release and 
maturation are essential for the completion of the life cycle and each process poses 
as a possible drug target. These processes are described briefly.  
1.5.1 Viral Entry 
Env glycoproteins, gp120 and gp41 mediate fusion of the viral and host cell 
membranes and ultimaltely viral entry into the target cell [27]. The interaction between 
the viral gp120 and the host CD4 induces several conformational changes that 
include the exposure of co-receptor binding sites on gp120 [49-51]. The co-receptor 
binding sites are recognized by chemokine co-receptors, CXCR4 and/or CCR5 [51-
53]. Following the gp120-co-receptor interaction, the gp120 component is shed and 
the gp41 hydrophobic fusion peptide or ectodomain becomes exposed [27] [50, 54]. 
The gp41 fusion peptide then folds over to acquire a coiled conformation which is 
known as a six helix bundle which results in the fusion of both membranes and entry 
of the viral core particle into the host cell [55]. 
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1.5.2 Host cell proteins involved in HIV-1 entry 
1.5.2.1 CD4 receptor 
 
CD4 is a glycoprotein that is expressed on the surface of some T lymphocytes. CD4 
is made up of an intracellular cytoplasmic domain, transmembrane domain and an 
extracellular unit of four domains comprising of two constant and two variable 
immunoglobulin-like domains [56] [57]. CD4 assists in T lymphocyte activation and is 
able to elicit an efficient immune response by directly interacting with Major 
Histocompatibility complex (MHC) class II on Antigen Presenting Cells (APCs) via its 
first variable domain (D1) [58-60]. The intracellular domain is involved in the initiation 
of signalling cascades within an activated T lymphocyte [61].  HIV-1 uses CD4 as its 
primary receptor to gain entry into the host cells [49, 62, 63] by binding to the amino 
terminal of D1 on the CD4 receptor via specific residues on its outer Env glycoprotein 
gp120 [64-66].   
1.5.2.2 CXCR4 and CCR5 co-receptors 
 
CXCR4, a α-chemokine receptor expressed on T lymphocytes and CCR5, a β-
chemokine receptor expressed on T lymphocytes and macrophages, are part of the 
seven transmembrane G-protein coupled receptor family [67-69].  CXCR4 was 
discovered as a co-receptor used by HIV-1 during entry and the discovery of CCR5 
as another co-receptor used by macrophage-tropic HIV-1 isolates followed [52, 53, 
68, 70].  HIV-1 entry into host cells and subsequent replication is efficient only in the 
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presence of a chemokine co-receptor [53, 70, 71].  The first and second extracellular 
loops of CXCR4 and the second and third extracellular loops of CCR5 have been 
shown to play an important role during gp120 binding and HIV-1 entry [72] [73].   
 
The type of co-receptor used depends on the cell type and phase of HIV-1 infection 
and contributes to the pathogenesis of virus [55]. HIV-1 transmissible Macrophage 
(M)-tropic strains or non-syncytia inducing strains (NSI) utilize the CCR5 co-receptor 
while HIV-1 T lymphocyte (T)-tropic strains or syncytia-inducing strains (SI) utilize the 
CXCR4 co-receptor [52, 53, 68]. During subtype A, B and D infection, M-tropic strains 
occur predominantly during early infection and T-tropic strains predominate during the 
later stages of infection resulting in accelerated disease progression to AIDS [74, 75] 
[76]. During the transition of M-tropic strains to T-tropic strains,  the emergence of 
dual tropic viruses (R5X4) may also occur [76] [77]. In contrast to the switch in 
tropism observed, previous studies have demonstrated that M-tropic viruses 
predominate at various stages of HIV-1 subtype C infection and that T-tropic viruses 
are quite rare even during the later stages of infection [78, 79], although an increase 
in T-tropic viruses has been described recently [80]. Interestingly, a recent study 
showed that ARV exposed subtype C isolates from Zimbabwe exhibited a T-tropic 
phenotype, suggesting that the ARV therapy may have possibly created an 
environment that stimulates the emergence of T-tropic viruses [81].    
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1.5.3 Viral proteins involved in HIV-1 entry 
1.5.3.1 Envelope glycoproteins 
 
Env glycoprotein gp160 precursors are processed within the rough endoplasmic 
reticulum (ER) [27, 82] followed by a series of modifications such as disulphide bond 
formation and the addition of N-linked high mannose oligosaccharides [82, 83]. 
Trimers of gp120 and gp41 are generated after gp160 is cleaved by host proteases in 
the Golgi apparatus [82, 84-86]. Non-covalent interactions exist between the gp41 
hydrophobic ectodomain and the amino and carboxyl terminals of gp120, which 
further facilitate the shedding of gp120 from the virion post CD4 binding [27, 87].  
Mature Env glycoproteins are formed in the Golgi apparatus once the gp120 subunit 
is glycosylated (addition of complex sugars) [83]. Mature Env glycoproteins are then 
transported to the host cell membrane where they are acquired along with host 
phospholipids by the viral particles upon budding [27]. The gp120 component is 
exposed on the viral membrane surface while gp41 component spans the membrane 
[27].  
1.5.3.2 The structure of HIV-1 gp120 
 
The conformationally flexible gp120 glycoprotein consists of five disulphide-linked 
hypervariable domains or loops (V1, V2, V3, V4 and V5) which are exposed on the 
viral surface, with five highly conserved regions (C1, C2, C3, C4 and C5) that are 
buried within the gp120 core [27, 83, 88-90]. The gp120 core is composed of an inner 
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domain containing the V1 and V2 loops that interact with the gp41 subunit, a four-
stranded beta-bridging sheet containing the co-receptor binding site and a highly 
glycosylated outer domain containing the V3 and V4 loops exposed on the viral 
surface [27]. Both the inner and outer gp120 domains contribute to CD4 interactions 
[27].  
 
Exposure of the highly conserved co-receptor binding sites induced by the binding of 
gp120 to the CD4 receptor on T lymphocytes requires the movement of the V1, V2 
and V3 loops [91]. The V1 and V2 regions are within close proximity of one another 
and are believed to shield the V3 region [91]. The absence of the V1/V2 regions has 
been shown to increase viral susceptibility to neutralizing antibodies [91]. The V3 
region has been the major focus of many studies since it contains an important 
neutralization domain and is able to co-ordinate co-receptor usage [71, 92-95]. This 
region is highly immunogenic and therefore exposed to strong immune pressures that 
increase its antigenic diversity [96]. 
1.5.3.3 Interactions between gp120-CD4 and gp120-co-receptors 
 
It has been shown that CD4 receptors form hydrogen bonds with amino acid residues 
that surround a deep pocket in gp120 via Phenylalanine-43 which has been shown to 
be extremely important for gp120 binding [27, 65, 97, 98]. In addition, the interaction 
between Asparagine-368 on gp120 and Arginine-59 on CD4 is believed to be 
important for gp120-CD4 interactions [27, 65, 97, 98]. Even though the V3 loop has 
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been implicated as the major determinant of co-receptor usage, there is evidence 
implicating the involvement of other gp120 conserved regions in co-receptor usage 
[51, 71, 99].  
1.5.3.4 The structure of HIV-1 gp41 and the fusion process 
 
In addition to its role in mediating fusion of the host and viral cell membranes, gp41 is 
also involved in the trimerization of Env glycoproteins [100]. It consists of an 
ectodomain (N-terminal) which contains a hydrophobic fusion peptide, a tryptophan-
rich membrane-spanning anchor and a cytoplasmic tail [85]. The ectodomain is a 
coiled coil structure which is believed to undergo conformational changes that 
ultimately allow fusion and viral entry [85, 101].  
 
Subsequent to the gp120-co-receptor interaction, the gp41 fusion peptide is exposed 
and inserted into the host cell membrane [85, 102, 103], leading to the formation of a 
pre-hairpin intermediate which consists of a two-heptad repeat (HR) region, an N-
terminal HR region within the host cell membrane and a C-terminal HR region within 
the viral membrane [103, 104]. Three parallel N-terminal HRs form a coiled-coil 
structure that lies anti-parallel to three C-terminal HRs. Interhelical interactions 
between the N-terminal HRs and C-terminal HRs result in the formation of the six-
helix bundle which pulls the viral and host cell membranes towards each other, 
thereby mediating fusion [85, 103]. A fusion pore that facilitates the passage of the 
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viral core into the host cell develops during the assembly of the six-helix bundle [105, 
106]. 
1.5.4 Viral replication, assembly and budding 
 
Post viral fusion, the viral core is uncoated and the genetic material along with 
essential viral proteins and enzymes are released into the cytoplasm [107]. RT 
converts each of the ssRNA molecules into dsDNA with the help of host deoxy-
nucleotriphosphates (dNTPs) [108]. Subsequently, a Pre-Integration Complex (PIC) 
including the complementary dsDNA, integrase, matrix protein and Vpr is formed 
[109, 110]. Vpr proteins contain nuclear localization signal sequences within the PIC 
and subsequently assist in importing the complex into the nucleus where it can be 
integrated into the host genome [111]. Integrase facilitates the translocation of the 
PIC through the nuclear pores and the integration of the dsDNA into the host genome 
where it is transcribed and expressed along with the host’s genes [109, 112, 113]. 
Rev proteins recognize viral mRNA transcripts and export them from the nucleus into 
the cytoplasm where they are protected from degradation, spliced and translated into 
viral proteins [40, 114]. All newly synthesized viral structural Gag proteins and 
enzymes migrate to lipid rafts within the plasma membrane where the assembly of 
immature virions takes place [115]. A lipid membrane is acquired from the infected 
host cell [27] and maturation of immature virions during budding out of the host cell 
relies on the complete proteolytic cleavage of the Gag and Gag-Pol proteins by the 
viral protease [116, 117]. 
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1.6 HIV-1/AIDS disease progression 
 
HIV-1 infection and disease progression in the absence of HAART usually occurs via 
distinct stages or phases and since the rate of HIV-1 disease progression to AIDS is 
dependent on numerous factors such as host immune responses, host and viral 
genetics and co-infections, the state of disease therefore varies with each individual 
[118-121]. The first phase, known as the acute or primary phase is characterized by a 
decrease in CD4+ T lymphocytes caused by rapid viral replication which in turn 
correlates with an increase in cytotoxic CD8+ T lymphocytes [122]. It is during this 
phase that seroconversion takes place [122]. The chronic or asymptomatic phase 
which can last up to 10 years is accompanied by the stabilization of viral replication. 
This causes plasma viral loads to reach a viral set point that ultimately defines the 
rate of disease progression to AIDS [123, 124]. During the asymptomatic phase, the 
levels of circulating CD4+ T lymphocytes normalize, however, intense immune 
activation as well as a gradual decrease in CD4+ T lymphocytes leads to the 
deterioration of the immune system which increases the host’s susceptibility to 
opportunistic infections resulting in the progression to AIDS [123-126]. The final AIDS 
phase is associated with an increase in viral load which correlates with a decrease in 
CD8+ T lymphocytes and in the production of neutralizing antibodies [123, 127]. 
During the course of HIV-1 infection, there is a loss of both infected and uninfected 
CD4+ T lymphocytes and several processes are known to contribute. However, one 
of the main strategies that HIV-1 utilizes to attack the immune system is its ability to 
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manipulate and disrupt the balance of apoptosis, which is a host cell defence 
mechanism [123]. Apoptosis, during the chronic phase of HIV-1 infection has been 
proposed as one of the processes that contribute to the depletion of uninfected CD4+ 
T lymphocytes and an increase in CD4+ T lymphocyte depletion correlates with an 
increase in disease progression [128-131]. Furthermore, HAART has been shown to 
reduce the levels of CD4+ T lymphocyte apoptosis within infected individuals [132, 
133].  
   
1.7 HIV-1 - mediated bystander CD4+T lymphocyte apoptosis  
 
Several HIV-1 encoded proteins are able to induce apoptosis (extrinsically or 
intrinsically) of both infected and uninfected T lymphocytes during HIV-1 infection via 
several mechanisms [134]. HIV-1 mediated apoptosis of uninfected bystander T 
lymphocytes is believed to be the cause of CD4+ T lymphocyte depletion since the 
number of infected lymphocytes is less than the number of lymphocytes undergoing 
apoptosis [135]. In addition, apoptosis of uninfected bystander T lymphocytes has 
been observed in the peripheral blood and lymph nodes of HIV-1 infected individuals 
and similar results were obtained in animal models [136-138]. Uninfected bystander T 
lymphocyte death can occur via the direct/indirect influence of HIV proteins, which are 
released by infected lymphocytes, or by activation-induced cell death (AICD), which is 
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caused by continuous antigenic stimulation and is mediated by the Fas-FasL pathway 
[132, 139]. 
 
This phenomenon has been intensely researched for more than a decade, however 
the true mechanisms are not fully understood and therefore HIV-1-mediated 
apoptosis of CD4+ T lymphocytes remains a controversial issue.  
1.7.1 Apoptosis 
 
Apoptosis, also known as programmed cell death, is a complex and highly regulated 
process that results in the self-destruction of cells in response to receptor mediated 
(extrinsic) or non-receptor mediated (intrinsic) signals, [134, 140]. Apoptosis is not 
only required for the regulation of normal physiological and developmental processes 
of multicellular organisms but also for the elimination of harmful cells [141, 142]. Cells 
that are undergoing apoptosis are characterized by chromosome condensation and 
fragmentation, phosphotidylserine (PS) externalization, mitochondrial membrane 
disruption, cell shrinkage and cell fragmentation ultimately leading to the formation of 
‘apoptotic bodies’ [134, 140, 143]. During apoptosis, serine proteases known as 
cysteine-dependant aspartate-specific proteases (caspases) are activated by 
proteolytic cleavage of their procaspase forms [134, 144, 145]. Activated caspases 
act as catalysts and mediate apoptosis by cleaving and inactivating protein substrates 
which are normally essential for the prevention of apoptosis [134, 144, 145]. In 
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addition, cleavage of the linker DNA between nucleosomal units occurs during the 
later stages of apoptosis, resulting in the fragmentation of DNA into multiples of the 
180 base pair (bp) nucleosomal unit [146]. 
  
1.7.1.1 Extrinsic Apoptosis and HIV-1 infection 
 
Extrinsic apoptosis requires an external death signal that interacts specifically with 
death receptors on cell surfaces [147]. Death receptors (DR), belonging to the Tumor 
Necrosis Factor Receptor (TNFR) superfamily include Fas (CD95), TNF receptor 1 
(TNFR1) and 2 (TNFR2) [147] and TNF-related apoptosis inducing ligand (TRAIL) 
receptors DR4 and DR5 [147-150]. These death receptors consist of a cysteine-rich 
extracellular domain and an intracellular cytoplasmic death domain (DD) (conserved 
sequence) which is involved in the recruitment of adaptor molecules, such as Fas-
associated DD (FADD) and the formation of a death-inducing signaling complex 
(DISC) [148]. Each death receptor interacts with its cognate death ligand, for 
example: FasL interacts with Fas DR [151], undergoes trimerization and subsequently 
activates a caspase-dependent signalling cascade that terminates in apoptosis [148].  
 
Briefly, the Fas cell death pathway requires the binding of the Fas ligand (FasL) to the 
Fas death receptor resulting in the formation of Fas trimers which activate the death 
receptor [148, 151]. The activated death receptor then recruits the adaptor molecule 
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Fas-associated DD (FADD) via DD signalling. Further interactions of FADD with 
cytosolic proteins as well as procaspase 8 leads to the formation of a death-inducing 
signalling complex (DISC) [148]. The formation of this complex leads to the activation 
of caspase 8 which in turn activates effector caspases; 6, 7 and 3 [144, 145]. 
Activated caspase 3 cleaves specific cellular substrates that include DNA repair 
enzymes and cytoskeletal proteins which ultimately results in cell death [144]. The 
DR5/DR4 and TNFR1 cell death pathways occur in the same manner as the Fas cell 
death pathway in the presence of TRAIL and TNF ligands, respectively. 
 
During HIV-1 infection, TRAIL has been found to be expressed by macrophages, 
monocytes and neurons [152-154] while Fas, FasL and TNF have shown to be 
expressed by macrophages, CD4+ and CD8+ T lymphocytes and in the patient 
plasma [155-157]. Studies have shown an increased expression of FasL, TNF, 
TNFR1 and TNFR2 within HIV-1 infected individuals and the resulting increase in 
Fas, TNFR1 and TNFR2-mediated apoptosis of CD4+ and CD8+ T lymphocytes has 
been correlated with disease progression [155, 156]. Furthermore, natural killer cells 
are able to utilize the Fas-pathway to mediate the destruction of HIV-1 infected 
lymphocytes [158]. It is evident that TRAIL plays a major role during HIV-1 infection 
and has therefore been suggested as being responsible for the apoptosis of 
uninfected bystander CD4+ T lymphocytes within HIV-1 infected tissues [147].  
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1.7.1.2 Intrinsic Apoptosis and HIV infection 
 
Alternatively, the intrinsic Fas-independent pathway, which is also known as the 
mitochondrial-dependant apoptotic pathway, can be activated by intracellular and 
extracellular stress signals and is regulated by specific pro-apoptotic factors that 
belong to the Bcl-2 protein family (Table 1.1) [159-162]. These proteins regulate the 
permeability and membrane potential of the mitochondrial membrane by forming 
pores in the mitochondrial membrane, resulting in the influx of water which eventually 
leads to the rupturing of the outer mitochondrial membrane [163-165]. Subsequently, 
pro-apoptotic proteins and cytochrome c are released from the inter-membrane space 
into the cytosol [166-168]. Pro-apoptotic factors assist cytochrome c to form an 
apoptosome consisting of Apoptotic Protease Activating Factor 1 (APAF-1) and 
procaspase 9. This process initiates a caspase cascade similar to the extrinsic 
pathway that ultimately results in the activation of effector caspases (6, 7 and 3) and 
cell death [145]. DNA fragmentation and nuclear condensation is induced in a 
caspase-independent manner by the translocation of cytochrome c activated proteins, 
Apoptosis-inducing factor (AIF) and Endonuclease G (EndoG) from the mitochondria 
to the nucleus [161, 166, 169, 170]. If however, the signals transmitted from activated 
death receptors are too weak and are unable to result in the apoptosis of a cell, the 
signals are amplified via the mitochondrial apoptotic pathway. In this case, active 
caspase 8 cleaves and activates proapoptotic protein Bid producing a truncated Bid 
which moves into the mitochondria and interacts with proapoptotic proteins Bax and 
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Bak [171-173]. These proteins contain conserved domains which allow the formation 
of oligomers, resulting in the release of cytochrome c [174-177]. The downstream 
effects thereafter are identical to those described in the intrinsic pathway. 
 
The Bcl-2 family consists of anti-apoptotic proteins Bcl-2 and Bcl-XL and pro-
apoptotic proteins Bid, Bik, Noxa, Bim, Bax and Bak which regulate apoptosis by 
influencing cytochrome c release [159]. All anti- and pro-apoptotic proteins share 
homology in their Bcl2-homology domains [159]. The general functions of the Bcl-2 
proteins are described in Table 1.1 [159, 163, 178]. 
 
Table 1.1: General functions of pro-apoptotic and anti-apoptotic proteins that belong 
to the Bcl-2 family 
 
 
 
 
 
 
 
 
 
 
 
Bcl-2 family members 
 
 
Function in mitochondrial apoptosis 
 
References 
 
Anti-apoptotic Bcl-2 and 
Bcl-XL 
 
 
 
Prevent the release of cytochrome c 
 
[159, 163, 178] 
 
Pro-apoptotic Bid, Bax and 
Bak 
 
 
 
Promote the release of cytochrome c 
 
 
[159, 163, 178] 
 
Pro-apoptotic Bik, Noxa 
and Bim 
 
 
 
Inhibit Bcl-2 and Bcl-XL 
 
[159, 163, 178] 
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In addition to activating the extrinsic pathway, HIV-1 proteins have the ability to 
change the mitochondrial membrane potential by disrupting the balance between anti-
apoptotic and pro-apoptotic proteins. Increased TNF-α levels and consequent loss of 
mitochondrial membrane potential have been observed in acutely HIV infected 
individuals [166, 179-181]. In addition, Env-induced syncytia have been shown to 
undergo intrinsic apoptosis via Bax mediate loss of mitochondrial membrane potential 
[166, 179-181]. Within HIV-1 infected individuals, the levels of Bcl-2 expression are 
low, however this varies according to the stage of disease and may be related to 
immune activation or other factors, for example, TNF-α induced NF-кβ upregulation 
has been implicated in increased Bcl-2 expression and apoptosis prevention and 
establishment of viral reservoirs [182] [183]. In contrast, the levels of Bax [184, 185] 
and Bim [186] and Reactive Oxygen Species (ROS) [180, 187] are much higher in 
infected individuals. HIV-1 is able to induce the release of cytochrome c and AIF via 
the activation of the p53 pathway [184]. Furthermore, there have been reports of p53 
regulation of Bax [188-190] and Bak [189]. The impact of HIV-1 proteins on apoptosis 
is cell-type specific and these proteins can function as pro/anti- apoptotic molecules, 
depending on the scenario [134].  
1.7.2 The involvement of HIV-1 encoded proteins in bystander T cell apoptosis 
 
Both uninfected and infected CD4+ T cell death is believed to be caused by viral 
encoded proteins such as Tat, Nef, Vpr, protease, Vpu and gp120 [191, 192]. The 
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apoptotic properties of proteins that promote bystander T cell death are described 
briefly below: 
1.7.2.1 Tat, Nef, Vpr, protease and Vpu - induced apoptosis 
 
Tat, secreted by HIV-1 infected T lymphocytes, is involved in the induction of 
apoptosis in uninfected bystander T lymphocytes [193] by enhancing their 
susceptibility to Fas-mediated apoptosis by upregulating Fas/FasL [194-196] and by 
increasing TRAIL expression on monocytes and macrophages which then interact 
with uninfected bystander lymphocytes [152, 153]. Tat is also able to induce 
apoptosis intrinsically by upregulating caspases 8 expression, Bax expression and 
modulating caspase 10 expression [185, 197, 198] and downregulating or 
upregulating Bcl-2 [185, 199]. 
 
Nef is able to function as an anti or pro-apoptotic protein and with such control over 
the apoptosis process, is able to protect HIV-1 infected lymphocytes from CD8+ 
cytotoxic T lymphocytes (CTL) attack, and gp120-CD4 mediated apoptosis by 
downregulating the surface expression of Major Histocompatibility Complexes I (MHC 
I) [200] and CD4 [201], respectively, while promoting uninfected bystander 
lymphocyte death by inducing Fas ligand (FasL) expression [202]. 
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Vpr is able to induce apoptosis by causing G2/M transition phase cell cycle arrest in 
proliferating infected lymphocytes through the inactivation of a G2/M transition 
regulator [203-205] and is also able to interact directly with the mitochondrion 
permeability transition pore ultimately resulting in the release of cytochrome c [206, 
207]. Vpu disrupts the integrity of the cell membrane and ultimately, cell viability by 
forming ion channels in the cell membrane, promoting viral release/budding [208]. 
Vpu has also been implicated in bystander killing [209-211]. 
 
HIV-1 protease is predominantly a pro-apoptotic protein and has been shown to 
modulate the expression of caspase 8 by associating with the extrinsic Fas-
independent apoptotic pathway [212] and Bcl-2 [213] therefore promoting 
mitochondrial dysfunction within HIV-1 infected T lymphocytes. Similarly, Vpu 
downregulates CD4 and Bcl-XL [214] expression, compromises the integrity of the 
cell membrane by increasing its permeability [215] and promotes Fas-mediated 
apoptosis [216] within HIV-1 infected T lymphocytes. 
 
1.7.2.2 gp120-induced apoptosis 
 
Finally and most importantly, gp120 has been demonstrated as the major pro-
apoptotic HIV-1 protein that can be presented in a variety of forms [123, 192, 217-
219]. Each form is capable of engaging the CD4, CCR5 and/or CXCR4 receptors, 
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and signalling through these receptors can activate apoptotic pathways within both 
infected and uninfected CD4+ T lymphocytes [192, 220-224]. During the entry 
process, gp120 monomer is shed, allowing gp41 to mediate fusion [225]. Thus, in an 
infected individual gp120 exists as shed soluble gp120 (sgp120), intact gp120 on the 
virion and as newly formed gp120 assembled on the membrane of an infected CD4+ 
T lymphocyte [123, 192].  
 
Free sgp120, is able to induce apoptosis via CD4–mediated signalling and signalling 
via both the co-receptors on uninfected and infected T lymphocytes. In addition, 
gp120 (monomeric or trimeric/oligomeric) expressed on infected lymphocytes is able 
to interact with CD4 and both the co-receptors on uninfected T lymphocytes resulting 
in either apoptotic signalling or cell-cell fusion events i.e. the development of syncytia 
or the occurrence of an hemifusion event. Both sgp120 and membrane bound gp120 
are able to induce both extrinsic and intrinsic apoptotic pathways [192, 218, 219, 224, 
226-229]. Syncytia are huge multinucleated cells that eventually become unstable 
and undergo apoptosis [123, 192]. Internalized gp120 acts as an anti-apoptotic 
protein by assisting in the dowregulation of CD4 on host cell surface, preventing 
gp120-CD4 signalling that could result in apoptosis of the infected T lymphocyte 
[230].  
 
The ability of sgp120 to induce apoptosis through CD4 and/or the CCR5  or CXCR4 
co-receptors interactions has been investigated in uninfected CD4+ T lymphocytes, 
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monocyte derived macrophages (MDMs) and various other cell lines [220, 224, 231-
234] and the membrane tyrosine phosphatase CD45 has shown to be an important 
regulator [235]. Results show that sgp120 (R5 and/or X4-utilizing) can induce 
apoptosis in uninfected cell lines via the extrinsic pathway [224, 236] intrinsic pathway 
[237], caspase independent pathways [238], caspase dependent pathways [239], and 
by inducing an anergic state [240].  
 
Activation of the intrinsic pathway within uninfected CD4+ T cells induced by X4 
sgp120 interactions correlates with a significant alteration in the expression of 
proteins that are involved in mitochondrial functioning, cell metabolism, cytoskeleton 
and cell cycle [241]. Differences between R5 and X4 sgp120-induced apoptosis have 
been described. For example, apoptosis mediated by the R5 sgp120 does not involve 
the activation of MAPK p38, as does X4 sgp120 [231]. Furthermore, Perfettini et 
al.(2005)  found that X4 sgp120-mediated apoptosis was caspase-dependent and 
CD4 independent [219]. In contrast, Vlahakis et al.(2001)  and Algeciras-Schimnich et 
al.(2002) showed that X4 sgp120 interactions induced caspase-independent 
apoptosis and R5 sgp120 interactions resulted in caspase 8-dependent Fas-mediated 
apoptosis which was dependant on CD4 binding [238] [224].  
 
In addition to CD4+ T lymphocyte apoptosis, gp120 has been implicated as a major 
contributor to the apoptosis of neuronal cells [242-244]. This results in the 
development of neuronal damage and dementia within AIDS patients [245, 246]. 
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Chemokine co-receptors have also been shown to be involved in gp120-mediated 
apoptosis of neuronal cells and interestingly, thought to be CD4 independent [247, 
248].  RNA-activated protein kinase signalling has been suggested as a mechanism 
for gp120-mediated apoptosis of neurons [249]. However, in a recent study, the 
treatment of neuronal cells with a cytokine known as Platelet-derived growth factor 
(PDGF) was able to reduce the amount of gp120-mediated apoptosis within neurons 
[243]. In addition, gp120-mediated apoptosis of cardiomyocytes and hepatocytes 
have also been implicated as part of the complications induced by HIV-1 infection 
[250, 251].  
Studies that evaluate the ability of cell surface expressed gp120 to induce apoptosis 
in co-cultured uninfected cells show a similar trend to that seen with sgp120 [220, 
224, 252]. Interestingly, it has been reported that a productive infection is not required 
for the induction of apoptosis in uninfected T lymphocytes, but the presence of 
infected dying T lymphocytes is required instead [253]. 
 
Evidently, the gp120 - CD4 interaction activates various apoptotic proteins that 
participate in both extrinsic and intrinsic apoptotic pathways. Even though there is 
supporting evidence of sgp120-mediated apoptosis in uninfected T lymphocytes, the 
true mechanism of this process remains unclear. Understanding the apoptosis of 
uninfected bystander T lymphocytes could lead to the development of therapies that 
could decrease the levels of apoptosis and most importantly, maintain CD4+ T 
lymphocyte populations. 
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1.8 Study Perspective 
 
 Most studies have been conducted using subtype B gp120 and since subtype C is 
the predominant HIV-1 subtype worldwide, as well as in the heterosexual population 
in South Africa [15, 254], additional research on this subtype is required. The overall 
aim of this project is to evaluate and compare the ability of recombinant subtype B 
and C R5 Env glycoproteins to mediate apoptosis of Jurkat T lymphocytes via gp120-
CD4 signalling and of CD4+ T lymphocytes via gp120-CD4 and co-receptor CCR5 
signalling.   
 
This was achieved through the following objectives:  
 
1. To express, purify and characterize the R5 HIV-1 subtype B and C recombinant 
monomeric gp120 from isolates BaL (gp120BaL) and 96ZM651 (gp120ZM651) as well as 
the trimeric/oligomeric Ancestral subtype C gp140 (gp140AncC). 
2. To evaluate the ability of the purified recombinant gp120BaL, gp120ZM651 and gp140AncC 
to induce apoptosis of HIV-1 uninfected Jurkat T lymphocytes via engagement with 
the CD4 receptor, using flow cytometry. 
3. To examine the contribution of CD4 and/or CCR5 receptor engagement with the 
purified recombinant gp120BaL, gp120ZM651 and gp140AncC on triggering apoptosis of 
HIV-1 uninfected enriched CD4+ T lymphocytes [isolated from peripheral blood 
mononuclear cells (PBMC’s)], using flow cytometry. 
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 Mammalian cell lines, bacterial cell lines, expression plasmids, 
recombinant proteins and antibodies used in this study 
 
Human Embryonic Kidney (HEK) 293T adherent cells were available in our 
laboratory, and used for the expression of the recombinant HIV-1 Env glycoproteins. 
The human T cell leukemic, Jurkat Clone E6-1 (Jurkat T lymphocytes) suspension 
cell line was purchased from Highveld Biologicals, Catalogue number: 177 (South 
Africa), and used to determine Env-mediated apoptosis via CD4 binding. CD8 
depleted CD4+T lymphocytes were isolated from fresh buffy coats purchased from 
the South African National Blood Bank Services (SANBS), and each donor was used 
seperately to determine Env-mediated apoptosis via CD4 and co-receptor binding 
(buffy preparations were not pooled) . (No ethics was required for the use of the buffy 
coats from the SANBS (see ethics waiver in Appendix B). All mammalian cell lines 
were incubated in a water jacketed 37°C, 5% CO2 incubator.  
 
Escherichia coli (E .coli) DH5α cells were available for use in our laboratory, and used 
in the transformation experiments and preparation of Env expression plasmids.  
 
Env expression plasmids used in this study are described in Table 2.1 and the 
commercially available HIV-1 recombinant Env glycoproteins that were used in the 
Enzyme-Linked Immunosorbent Assays (ELISAs) are described in Table 2. 2. 
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Affinity purified sheep anti-HIV-1 gp120 (D7324; Aalto Bio Reagents Ltd, Ireland) was 
used to coat 96-well ELISA plates (Nunc, Roskilde, Denmark) for the capture of 
gp120BaL, gp120ZM651 and gp140AncC in the capture ELISAs. The primary and 
secondary antibody probes used in the ELISAs for the conformational and functional 
analyses of the purified recombinant glycoproteins are described in Table 2.3. In 
addition, the antibodies used in the Western Blot analyses are described in Table 2.4.    
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Table 2.1: Expression plasmids used for the transient expression and purification of monomeric and trimeric/oligomeric 
recombinant HIV-1 Env glycoproteins. 
 
 
 
 
EXPRESSION 
PLASMID 
 
CATALOGUE 
NUMBER 
 
AKNOWLEDGEMENT 
 
PURPOSE IN THE STUDY 
 
HIV-1 
p96ZM651gp120-
CD5-opt (subtype C) 
expression plasmid 
 
8661 
Obtained from the NIH AIDS Research 
and Reference Reagent Program, 
Division of AIDS, NIAID, NIH: 
p96ZM651gp120-CD5-opt from Drs 
Yingying Li, Feng Gao and Beatrice H. 
Hahn 
 
Transient expression and purification 
of monomeric recombinant 
96ZM651gp120 (gp120ZM651) 
HIV-1 pciNEO-
BaLgp120 (subtype B) 
expression plasmid 
 
 
N/A 
Available in our laboratory  Transient expression and purification 
of monomeric recombinant 
BaLgp120  (gp120BaL)  
 
Ancestral subtype C 
gp140 expression 
plasmid 
 
 
N/A 
Obtained from Dr Richard Wyatt, 
Vaccine Research Centre, NIH 
Transient expression and purification 
of trimeric/oligomeric recombinant 
gp140 (gp140AncC) 
 
Empty pcDNA 3.1 
expression plasmid 
(mock control) 
 
 
N/A 
Available in our laboratory  Transient expression and purification 
of a mock control which was used in 
apoptosis assays. 
 
 33 
Table 2.2: Recombinant proteins used in the ELISAs and Western Blot analyses. 
 
 
RECOMBINANT 
PROTEINS 
 
CATALOGUE 
NUMBER 
 
AKNOWLEDGEMENT 
 
PURPOSE IN THE STUDY 
 
 
HIV-196ZM651gp120 
 
10080 
 
Obtained from the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, 
NIAID, NIH: HIV-196ZM651gp120 from DAIDS, 
NIAID 
 
Positive control in Western 
blots and ELISAs 
 
HIV-1BaLgp120 
 
4961 
 
Obtained from the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, 
NIAID, NIH: HIV-1BaLgp120 from DAIDS, NIAID 
 
Positive control in Western 
blots and ELISAs 
 
Full length soluble 
CD4 (sCD4) 
 
N/A 
 
Obtained from Progenics Pharmaceuticals Inc. 
Lot# 63 
 
Confirm CD4 binding of  
recombinant gp120ZM651 in 
CD4 binding ELISAs  
 
 
Wild type two 
domain soluble CD4 
(wt2dsCD4)  
 
 
N/A 
 
Available in our laboratory 
 
Conformational analysis  
of the recombinant HIV-1 
Env glycoproteins using 
capture ELISAs 
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Table 2.3: Primary and secondary antibodies used in the ELISAs  
 
 
ANTIBODIES CATALOGUE 
NUMBER 
ACKNOWLEDGEMENT PURPOSE IN 
THE STUDY 
Human HIV-1 gp120  
Monoclonal antibody (MAb) 
(IgG1 b12) 
2640 Obtained from the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 
gp120 MAb (IgG1 b12) from Dr. Dennis Burton and 
Carlos Barbas 
 
Primary 
antibody used 
in capture 
ELISAs 
Human HIV-1 gp120 MAb 
(17b) 
4091 Obtained from the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 
gp120 MAb (17b) from Dr. James E. Robinson 
 
Primary 
antibody used 
in capture 
ELISAs 
Human HIV-1 gp120 MAb 
(2G12) 
1476 Obtained from the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 
gp120 MAb (2G12) from Dr. Hermann Katinger 
 
Primary 
antibody used 
in capture 
ELISAs 
Human HIV-1 gp120 MAb 
(48D) 
1756 Obtained through the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, 
NIH: HIV-1 gp120 MAb (48d) from Dr. James E. 
Robinson 
 
Primary 
antibody used 
in CD4 binding 
ELISAs 
ECLTM Anti-human IgG 
Horseradish peroxidase 
(HRP)-linked whole 
antibody (from sheep) 
NA933V Obtained from GE Healthcare UK Limited, Little 
Chamfont Buckinghamshire, England 
Secondary 
antibody used 
in all ELISAs 
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Table 2.4: Antibodies used during Western Blot Analyses for the detection of recombinant HIV-1 Env glycoproteins. 
 
 
 
ANTIBODIES 
 
CATALOGUE 
NUMBER 
 
AKNOWLEDGEMENT 
HIV positive plasma 16 and 20 (primary antibody used) 
 
N/A 
 
Obtained from SANBS 
Anti-human IgG (Fc specific) Alkaline phosphatase 
conjugate (from goat) (secondary antibody used) 
 
 
A-9544 
Obtained from Sigma-Aldrich, 
Steinheim, Germany 
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All antibodies used in the flow cytometric analyses (shown below in Table 2.5) were 
obtained from Beckman Coulter Inc, Fullerton, CA, USA.  
 
Table 2.5: Flow cytometry antibodies used during the detection of early/late apoptosis 
and DNA fragmentation. 
 
 
ANTIBODIES 
 
PART 
NUMBER 
 
PURPOSE IN THE STUDY 
R-Phycoerythrin (PE)-labelled anti-
CD4 antibody probe (IOTest® CD4-
PE) (CD4-PE) 
 
 
IM0449U 
Confirm the presence of CD4+ 
lymphocytes (from blood and 
Jurkat T lymphocytes)  
 
Phycoerythrin-Texas Red-X (ECD)-
labelled CD8 antibody(Cyto-
Stat®/Coulter Clone®T8-ECD) (CD8-
ECD) 
 
 
6604728 
Confirm the depletion of CD8+ 
T lymphocytes 
Phycoerythrin-Cy7 (PC7)-labelled 
CD3 antibody (IOTest® CD3-PC7) 
(CD3-PC7) 
 
 
6607100 
Used for the selection of CD3+ 
CD4+ CD8- T lymphocytes 
 
2.2 Isolation of gp120BaL, gp120ZM651 and gp140AncC plasmid DNA 
2.2.1 Production of competent E. coli DH5α cells 
 
Under sterile conditions, 10µl of E. coli DH5α cells were added to 10ml of Luria 
Bertani (LB) broth (Appendix A.1) incubated in a shaking incubator overnight at 37°C 
and subsequently diluted 40 times with fresh LB broth before being incubated at 37°C 
 37 
for another hour in a shaking incubator. This was to allow optimal growth and to 
obtain an optical density of 0.4 at 600nm. Cell cultures were centrifuged at 300xg for 
10 minutes at 4°C, the cell pellet was resuspended in 10ml of ice-cold transformation 
buffer (Appendix A.1), incubated on ice for 30 minutes and centrifuged again at 300xg 
for 10 minutes at 4°C. Finally, the supernatant was discarded and the bacterial cell 
pellet was resuspended in 1ml of ice-cold transformation buffer.  Competent E. coli 
DH5α cells were stored at -80°C in 100µl aliquots until required for use.  
2.2.2 Bacterial transformation with Env expression plasmids 
 
Under sterile conditions, 2µl of each Env expression plasmid (gp120BaL, gp120ZM651 or 
gp140AncC) was incubated with 25µl of competent E. coli DH5α cells for 30 minutes on 
ice. The mixture was then heat shocked in a 42°C water bath for 90 seconds and 
200µl of LB broth was added to the cells. The cells were incubated at 37°C in a 
shaking incubator for an hour before being spread onto LB agar plates containing 
100µg/ml ampicillin (Appendix A.1.) using a sterile glass rod. The plates were then 
incubated overnight at 37°C. Ampicillin resistant, transformed E. coli DH5α cells 
(those containing the plasmids) grew as single colonies on the agar plate and a single 
bacterial colony was picked off the plate, inoculated into 250ml of fresh LB broth 
containing 100µg/ml ampicillin and incubated on a shaker at 37°C overnight. Glycerol 
stocks of gp120BaL, gp120ZM651 and gp140AncC transformed E. coli DH5α cells were 
produced under sterile conditions and stored in cryovials (Nunc, Roskilde, Denmark) 
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at -80°C until required for use. Briefly, 200µl of 100% glycerol (Merck, Hohenbrunn, 
Germany) was added to 800µl of each culture, and mixed well. The glycerol protects 
the bacterial cells from being punctured and killed by ice crystals that form in the LB 
broth during freezing.  
2.2.3 Large scale expression plasmid preparations 
 
Recombinant gp120BaL, gp120ZM651 and gp140AncC expression plasmids were 
extracted from the overnight cultures produced (mentioned in section 2.2.2), using a 
Qiagen QIAfilterTM Plasmid Maxi Kit (Qiagen, Maryland, USA) according to the 
manufacturer’s instructions. Briefly, the overnight cultures were centrifuged at 6000xg 
for 15 minutes and the pellet was resuspended in Buffer P1 (Appendix A.1.2) to 
produce a homogenous mixture. Buffer P2 (Appendix A.1.2) was then added to the 
homogenous mixture to lyse and denature the bacterial cells for the release of the 
plasmids, subsequently mixed vigorously and incubated at room temperature for 5 
minutes before chilled buffer P3 (Appendix A.1.2) was added. Buffer P3 neutralizes 
and renatures the plasmid DNA.  
 
After vigorously inverting a few times, the lysate was poured into QIAfilterTM maxi 
cartridges and incubated at room temperature for 10 minutes. During this time, a 
QIAGEN-tip 500 was equilibrated with QBT buffer (Appendix A.1.2) by gravity flow to 
prepare the column for plasmid DNA binding. The cap at the outlet nozzle of the 
 39 
QIAfilterTM cartridge was removed and the plunger was gently inserted into the filter 
allowing the cell lysate to be filtered through the previously equilibrated QIAGEN-tip 
500. The cell lysate filtered through the resin by gravity flow and the QIAGEN-tip 500 
was then washed twice with buffer QC (Appendix A.1.2). The plasmid DNA was then 
eluted with buffer QF (Appendix A.1.2) and precipitated by the addition of isopropanol 
(Merck, Hohenbrunn, Germany). After mixing the eluted DNA in the isopropanol, the 
plasmid DNA was centrifuged at 15000xg for an hour at 4°C. The supernatant was 
carefully discarded and the pellet was washed with room temperature 70% ethanol 
(Merck, Hohenbrunn, Germany) (Appendix A.1) and centrifuged again at 15000xg for 
30 minutes at 4°C.  
 
The supernatant was carefully discarded and the pellet was air dried completely 
before being dissolved in sterile Sabax water (sH2O) (Dismed Criticare, Midrand, 
South Africa). The concentration of the isolated recombinant gp120BaL, gp120ZM651 
and gp140AncC plasmid DNA was measured spectrophotometrically (Nanodrop 
Technologies Inc; Wilmington, DE) and stored at -20ºC until used for the transfections 
of mammalian HEK 293T cells.  
 
The isolated recombinant gp120BaL, gp120ZM651 and gp140AncC plasmids DNA were 
resolved on 0.8% agarose (Sigma-Aldrich, Steinheim, Germany) gels (Appendix 
A.1.3) submerged in 1XTris-Acetate-EDTA (TAE) buffer (Appendix A.1.3) using the 
Bio-Rad Gel Tank System (Bio-Rad; Hercules, CA). Each DNA sample, including the 
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O’ GeneRulerTM DNA ladder mix (range 50bp-10kb) (Fermenta, Ontario, Canada), 
was mixed with 6X DNA loading buffer (Appendix A.1.3) before being loaded into the 
wells in the gel. The gels were resolved at a current of 100V for approximately 1.5 
hours and subsequently visualized under UV light using the VersadocTM Imaging 
System (Bio-Rad; Hercules, CA) to ensure that the expression plasmids were present 
and not degraded.    
2.3 Expression of recombinant gp120BaL, gp120ZM651 and gp140AncC 
using mammalian HEK 293T cells 
2.3.1 Maintenance of HEK 293T cell lines 
 
The HEK 293T adherent cell line was propagated in 75cm3 flasks (Nunc, Roskilde, 
Denmark)  and maintained in complete Dulbecco’s Modified Eagle Medium (DMEM) 
(Sigma-Aldrich, Steinheim, Germany) [DMEM supplemented with 10% heat-
inactivated fetal calf serum (FCS) (Gibco; Grand Island, USA), L-Glutamine (200nM) 
(Gibco; Grand Island, USA), Penicillin (1000µg/ml) and Streptomycin (1000µg/ml) 
(Gibco; Grand Island, USA)].  
 
HEK 293T cells were split when confluent, and diluted as required. The complete 
DMEM was discarded and the cells were washed with 5ml of 1X Dulbecco’s 
Phosphate Buffered Saline (PBS) (no calcium chloride and magnesium chloride) 
(Sigma-Aldrich, Steinheim, Germany) and trypsinized with 1ml of 0.25% 
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Trypsin/EDTA (Sigma-Aldrich, Steinheim, Germany) for one minute at room 
temperature and then for 2-5 minutes in a 37°C incubator. Thereafter, 10ml of 
complete DMEM was added to inactivate the trypsin (FCS inactivates trypsin) and to 
gently resuspend the cells and disperse any clumps. Finally, the cells were diluted ten 
times (or as required) in fresh complete DMEM: 9ml of cells were discarded or 
transferred as 1ml aliquots into new 75cm3 flasks, and 9ml of fresh complete DMEM 
were added to each ml of split cells.  
2.3.1.1 HEK 293T cell stocks 
 
HEK 293T cell stocks were prepared in a filter sterilized (0.22 μM Acrodisc® 25 mm 
syringe filters; Pall Corporation, Ann Arbor, USA) freezing mix (Appendix A.2). Briefly,  
trypsinized cells were resuspended in complete DMEM, centrifuged at 200xg for 10 
minutes and subsequently resuspended in freezing mix, ensuring that there were 
1X106 cells/ml. Cell stocks were transferred into the NalgeneTM Cryo 1ºC freezing 
container (USA) and stored at -80ºC overnight to ensure a -1ºC/min rate of cooling. 
The isopropanol within the freezing container was replaced each time before use. 
Finally, the cell stocks were transferred into a separate storage container at -80ºC for 
short storage periods or into liquid nitrogen for longer storage periods. HEK 293T cell 
lines were discarded after 20 passages, and new cell lines were propagated from 
frozen cell stocks.  
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2.3.1.2 HEK 293T cell counting 
 
Trypsinised HEK 293T cells were counted using trypan blue solution (Sigma-Aldrich; 
Steinheim, Germany) on a haemocytometer to ensure cell viability and that the 
appropriate numbers of cells were used in the various assays. The cells were diluted 
five times with 0.4% trypan blue solution, counted under an inverted light microscope 
and the average number of cells was obtained. The average was then multiplied by 
the dilution factor (5) and divided by the volume of the haemocytometer (1 X 10-4 cm3) 
to obtain the amount of cells/ml.  The number of cells/ml was then multiplied by the 
total volume of cells collected to obtain the final amount of cells.  
2.3.2 Optimisation of transfection conditions in HEK 293T mammalian cells 
 
At approximately 70-80% confluency, HEK 293T cells were split (as outlined in 
section 2.3.1), counted (as outlined in section 2.3.1.2), seeded at 2.5 x 106 cells in 
20ml of complete DMEM within a 75cm3 flask and transfected 24 hours later with 
recombinant gp120BaL or gp120ZM651 expression plasmids using either Calcium 
Chloride (CaCl2) (Appendix A2.1) or Polyfect® transfection reagent (Qiagen, 
Maryland, USA). Optimal transfection condition for gp140AncC are already established 
in our laboratory (using the Polyfect® transfection reagent), thus experiments for this 
protein were not repeated. 
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2.3.2.1 Transfections using CaCl2 
 
When using CaCl2, 62.5µl of 2.5M CaCl2 (Appendix A.2.1) and 500µl of 2X HEPES 
solution (Appendix A.2.1) was added to 10µg of recombinant plasmid DNA (either 
gp120BaL or gp120ZM651) and the mixture was subsequently made up to a total of 1ml 
with sH2O. The transfection complexes were then incubated at room temperature for 
15-20 minutes before being added to the medium in a drop-wise manner. The 
medium was then gently swirled over the surface of the adherent cells. A negative 
control was prepared in the exact same manner, but with the absence of plasmid 
DNA. The complete DMEM was replaced with 20ml of fresh medium 24 hours later 
and the cells were incubated for a further 48 hours before the DMEM containing the 
secreted proteins was harvested i.e. harvested at 72 hours. Since the proteins were 
secreted into the cell medium, supernatant samples (50µl) were taken at 24, 48 and 
72 hours for the detection of protein expression by Sodium Dodecyl Sulphate–
Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western blot analyses. 
2.3.2.2 Transfections using the Polyfect reagent 
 
When using the Polyfect® transfection reagent, 8µg of either gp120BaL or gp120ZM651 
was combined with 80µl of the Polyfect® transfection reagent and 300µl of 
incomplete DMEM (no additives). The combinations were incubated for 15 minutes at 
room temperature to allow the formation of transfection complexes and 1ml of 
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complete DMEM was subsequently added. The complexes were added to the culture 
medium of each flask, followed by gentle swirling of the medium over the surface of 
the adherent cells. A negative control was also prepared, as mentioned above in 
section 2.3.2.1. The procedure here after was performed in the exact same manner 
as in the CaCl2 transfections (section 2.3.2.1). Culture supernatant were harvested at 
72 hours and supernatant samples (50µl) were taken at 24, 48 and 72 hours for the 
detection of protein expression by SDS-PAGE and Western blot analyses. 
2.3.3 SDS-PAGE and Coomassie staining 
 
SDS-polyacrylamide gels (8%) comprising of an upper stacking and lower resolving 
gel component (Appendix A.3) were produced. Each sample (samples taken during 
the transfections or protein purification processes) (30µl) was combined with 2X 
loading buffer (30µl) (Appendix A.3), boiled for 5 minutes and cooled before being 
loaded onto duplicate SDS-polyacrylamide gels. The gels were submerged in running 
buffer (Appendix A.3) and exposed to a current of 10mA/gel until the dye front had 
passed through the stacking gel (for approximately 1 hour). The current was then 
increased to 20mA/gel and the gels were resolved over a period of 2 hours using the 
Amersham Biosciences Electrophoresis power supply EPS 301 power box.  One of 
the resolved SDS-polyacrylamide gels was stained with Coomassie® Brilliant Blue 
R250 (Sigma-Aldrich; Steinheim, Germany) (Appendix A.5) overnight at room 
temperature with gentle shaking. Staining was followed by the addition of a destaining 
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buffer (40% Methanol and 7% Acetic Acid) (Appendix A.5) which was incubated with 
the gel while gently shaking until it turned clear. The clear SDS-polyacrylamide gel 
was visualized under white light and photographed with the VersadocTM Imaging 
System (Bio-Rad; Hercules, CA) under white epiluminescence. 
2.3.4 Western blot analysis 
 
The second SDS-polyacrylamide gel was used for western blot analysis. All steps 
were carried out at room temperature. The gel, filter paper (Pierce, USA) and 
HybondTM-C-Extra nitrocellulose membrane (Amersham Biosciences UK Limited, 
Little Chatfont, England) were simultaneously equilibrated with transfer buffer 
(Appendix A.4) with gentle shaking at room temperature for 15 minutes. The proteins 
on the SDS- polyacrylamide gel were transferred onto the nitrocellulose membrane 
(Amersham Biosciences) using the Trans-Blot SD Semi-Dry Transfer Cell System 
(Bio-Rad, Hercules, CA) at a constant current of 250V, applied for 75 minutes. The 
membrane was subsequently blocked with 5% Blotting Grade Blocker (non-fat dry 
milk) (Biorad, Hercules, CA) in 50ml of 1X Tris-buffered saline (TBS) containing 0.1% 
Tween-20 (T-TBS) (Appendix A.4) overnight, and subsequently washed with 1X T-
TBS 3 times for 5 minutes each by moderate shaking. The membrane was then 
incubated with 50ml of 1X T-TBS containing 0.5% Bovine Serum Albumin (BSA) 
(Appendix A.4) and a 1:2000 dilution of the primary antibody, pooled human sera 16 
and 20 for 2 hours. The membrane was washed 3 times with 1X T-TBS for 5 minutes 
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each wash, was and then probed with the secondary Anti-human IgG (Fc specific) 
Alkaline phosphatase conjugate antibody (Sigma-Aldrich, Steinheim, Germany) at a 
1:30000 dilution in 30ml of 1X T-TBS containing 0.5% BSA for one hour. Finally, the 
membrane was washed 3 times with 1X T-TBS for 5 minutes each, and incubated 
with 2.5ml of the NBT/BCIP (Roche, Mannheim, Germany) solution (Appendix A.4) in 
the dark until the protein bands were visible. The reaction was terminated upon the 
addition of sH2O (Dismed Criticare). The western blot was photographed with the 
VersadocTM Imaging System (Bio-Rad; Hercules, CA) under white epiluminescence. 
All further transfection experiments using gp120BaL, gp120ZM651 and gp140AncC were 
performed using the Polyfect® transfection reagent as described in section 2.3.2.2. 
2.4 Purification and concentration of recombinant gp120BaL, 
gp120ZM651 and gp140AncC Env glycoproteins 
 
The expression of all three recombinant Env glycoproteins including a mock control 
(empty expression plasmid) was upscaled using the Polyfect® transfection reagent. 
During large scale Polyfect transfections, 293 Serum-Free media (SFM II) (Gibco; 
Grand Island, USA) (containing only 200nM L-Glutamine) was used as the 
replacement medium instead of complete DMEM, at 24 hours post transfection. The 
absence of serum proteins or antibiotics eliminates any cause of interference with the 
subsequent purification of the recombinant proteins. The harvested media from 
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transfections of each recombinant protein was clarified by centrifugation at 4000xg for 
10 minutes at 4°C, pooled and stored at -20ºC until purified (maximum of 3 days). 
2.4.1 The preparation of the column and purification procedure 
 
The Bio-Rad Biologic LP chromatography system (Bio-Rad, Hercules, CA) was used 
for the recombinant Env glycoprotein purification process. For each purification 
process, 200ml volumes of the clarified cell supernatants containing the expressed 
Env glycoprotein (gp120BaL, gp120ZM651 or gp140AncC) and supernatants from mock 
transfected cells were each purified using Galanthus nivalis lectin (Sigma-Aldrich, 
Steinheim, Germany) [255]. This can be accomplished due to the highly glycosylated 
external front of gp120, which possesses a high affinity for the lectin sugar residues. 
For preparation of the column, the lectin was resuspended in 1X PBS before being 
packed into a 2ml column (Sigma-Aldrich, Steinheim, Germany). Before loading the 
supernatant samples (gp120BaL, gp120ZM651, gp140AncC or mock control) onto the 
lectin column, the column was washed and equilibrated with 10ml of 1X PBS. The 
supernatant samples were pumped through an adaptor and onto the column at a flow 
rate of 2ml/minute. Once the sample had been loaded onto the column, the column 
was subjected to two washing buffers (1X PBS and 1M NaCl) (Appendix A2.2) for 75 
minutes at 2.5ml-3.5ml/min and finally the lectin-bound glycoprotein (gp120BaL, 
gp120ZM651 or gp140AncC) was eluted from the column using a 50ml 0.75M methyl α-
D-mannopyranoside (MMP) (Sigma-Aldrich, Steinheim, Germany) solution (Appendix 
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A2.2) at a flow rate of 2.5ml/minute. In addition, the mock control supernatant was 
purified in the same manner.  Separate lectin columns were used for each gp120BaL, 
gp120ZM651, gp140AncC or mock Env preparation to prevent cross contamination of 
proteins. 
2.4.2 Dialysis and concentration of the eluted recombinant Env glycoproteins 
 
The eluted Env glycoproteins (gp120BaL, gp120ZM651 or gp140AncC) and mock samples 
were transferred into Snakeskin® Pleated dialysis tubing (Thermo Scientific, 
Rockford, IL, USA) and dialyzed overnight in 2L of ice-cold 1X PBS at 4°C, with 
stirring. The following day, the 2L of 1X PBS was replaced with 2L of fresh, ice-cold 
1X PBS and the Env glycoproteins and mock samples  were dialyzed for a further 2-3 
hours and subsequently concentrated in Amicon® Ultra-15 Centrifugal Filter devices 
(Molecular Weight cut off 50 kDA) (Millipore, Billerica, MA) by centrifugation at 4000x 
g for 3 min at 4°C. The Amicon® Ultra-15 Centrifugal Filter devices were equilibrated 
with 15ml of ice-cold 1X PBS before concentrating the eluted samples (gp120BaL, 
gp120ZM651, gp140AncC or mock control). Excess amounts of MMP bound to the 
purified, concentrated Env glycoproteins or mock control was removed by 
centrifugation in ice-cold 1X PBS at 4000x g for 3 min at 4°Cand subsequently 
aliquoted and stored at -80ºC until required.  
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After every purification process, the lectin column was rinsed with 0.01% Sodium 
Azide (Sigma-Aldrich, Steinheim, Germany) (Appendix A2.2) to prevent the risk of 
contamination. The entire protein purification process was monitored by obtaining 
50µl aliquots of the clarified cell supernatants, flow through, washes, elutions and 
concentrated Env glycoprotein and mock control samples for SDS-PAGE and 
Western Blotting analyses (as described in Sections 2.3.3 and 2.3.4).  
2.5 Quantification of the recombinant gp120BaL, gp120ZM651 and 
gp140AncC  
 
The recombinant gp120BaL, gp120ZM651 and gp140AncC Env glycoproteins were 
quantified using the Pierce BCATM protein assay kit (Thermo Scientific, Rockford, IL, 
USA) and the procedure was performed as per manufacturer’s instructions. Briefly, 
Bovine Serum Albumin (BSA) standards (500µg/ml, 250µg/ml, 125µg/ml, 62.5µg/ml, 
31.25µg/ml, 15.625µg/ml, 7.8125µg/ml and 0µg/ml) were prepared in 1X PBS for the 
establishment of a standard curve. The standards (25µl) were added to a maxisorp 
ELISA plate (Nunc, Roskilde, Denmark) in duplicate. The concentrated gp120BaL, 
gp120ZM651 and gp140AncC samples were diluted 5 times in 1X PBS and 25µl was 
added to the ELISA plate in triplicate. In addition, the blank sample (1X PBS) was 
added to the ELISA plate in triplicate. A developing solution containing a 50:1 ratio of 
reagent A and B (Appendix A2.2) was prepared and 200µl was added to each sample 
in the plate. The ELISA plate was then incubated for 2 hours at 37°C in the dark with 
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gentle shaking and subsequently read by the Microplate reader Model 680 (Bio-Rad, 
Hercules, CA)  at an absorbance of 570nm. The absorbance readings were averaged 
and used to create a standard curve from which the concentration of recombinant 
gp120BaL, gp120ZM651 and gp140AncC was obtained.  
2.6 Conformational and functional assessments of the 
recombinant gp120BaL, gp120ZM651 and gp140AncC Env 
glycoproteins 
 
The conformational and functional integrity of the purified recombinant gp120BaL, 
gp120ZM651 and gp140AncC was evaluated by their ability to bind MAb’s IgG1b12, 2G12 
and 17b in the presence and absence of 2dWtsCD4, in capture ELISAs.  
 
A 96-well maxisorp ELISA plate (Nunc, Roskilde, Denmark) was coated for 3 hours at 
room temperature with 100µl/well of an Affinity purified sheep anti-HIV-1-gp120 
antibody (D7324) at a concentration of 1µg/ml in 1X PBS. The wells were emptied on 
paper toweling, before being blocked with 250µl/well of 1X PBS containing 0.05% 
Tween-20 and 10mg/ml Bovine Serum Albumin (PBS-T-BSA) (Appendix A.6) 
overnight at 4ºC. The blocking solution was removed by washing the plate 5 times 
with 1X PBS containing 0.1% Tween-20 (PBS-T) (Appendix A.6) and the wells were 
then incubated for 3 hours at room temperature with 100µl/well of either recombinant 
gp120BaL, gp120ZM651 or gp140AncC at final concentrations of 500ng/ml, 100ng/ml, 
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20ng/ml, and 4ng/ml (obtained by 5-fold dilutions of each recombinant protein in PBS-
T). 
 
Recombinant gp120BaL, gp120ZM651 or gp140AncC analysed for 17b binding in the 
presence of 2dWtsCD4 were produced at final concentrations of 1000ng/ml, 
200ng/ml, 40ng/ml, and 8ng/ml (obtained by 5-fold dilutions of each recombinant 
protein in PBS-T) and incubated with equal volumes of 2dWtsCD4 (2µg/ml) to ensure 
final concentrations of 500ng/ml, 100ng/ml, 20ng/ml, and 4ng/ml. This combination 
was incubated at room temperature for one hour before being added to the ELISA 
plate. Each protein concentration was analysed in duplicate. After washing the plate 5 
times with PBS-T, primary antibody probes IgG1b12, 2G12 and 17b were diluted 
1000 times in PBS-T, added to the relevant wells (100µl/well) and incubated for 2 
hours at room temperature. Unbound primary antibody probes were removed by 
washing 5 times with PBS-T. After washing, the ECLTM Anti-human IgG Horseradish 
peroxidase (HRP)-linked whole antibody probe was diluted 2000 times in PBS-T and 
100µl was added to all the wells. The ELISA plate was then incubated for 1 hour at 
4ºC. Unbound secondary antibodies were removed by washing 5 times with PBS-T 
and 100µl of the 1 step TM Ultra-TMB-ELISA substrate (Thermo scientific, Rockford, 
IL) was then added to each well and allowed to develop in the dark for approximately 
15-30 minutes. The blue reaction was terminated by the addition of 50µl of 2mM 
sulphuric acid (H2SO4) (Appendix A.6) resulting in the production of a yellow colour. 
The plate was read on the Microplate reader Model 680 (Biorad) at an absorbance of 
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450nm. This experiment was performed three times and similar results were obtained 
each time. 
 
All three recombinant Env glycoproteins were purified, quantified and characterised 
throughout the course of the study, as required.  
2.7 Confirmation that gp120ZM651 is able to bind CD4 efficiently 
 
The CD4 binding function of gp120ZM651 was further confirmed in a CD4 binding 
ELISA. The 96-well maxisorp ELISA plate was coated for 3 hours at room 
temperature with 100µl/well of full length sCD4 at a concentration of 1µg/ml in 1X 
PBS. The sCD4 was removed and the wells were blocked overnight with 250µl/well of 
1X PBS-T-BSA (Appendix A.6) at 4ºC. The wells were then washed 5 times with 
PBS-T and 100µl of gp120ZM651, gp120BaL, gp140AncCand HIV-196ZM651gp120 was 
added to each well in triplicate at a single concentration of 500ng/ml and incubated 
for 2.5 hours at room temperature. After washing the plate 5 times with PBS-T the 
human primary antibody probe 48D was diluted 500 times with PBS-T and 100µl was 
added to each well and incubated for 2 hours at room temperature. Any unbound 
primary antibody was removed by washing 5 times with PBS-T. Thereafter, the ECLTM 
Anti-human IgG Horseradish peroxidase (HRP)-linked whole antibody was diluted 
2000 times in PBS-T, and 100µl was added to the respective wells and incubated for 
1 hour at 4ºC. After washing 5 times with PBS-T, the reactions were developed and 
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the absorbance readings were measured using the method described in section 2.6. 
This experiment was performed three times and the results were consistent each 
time. 
2.8 Recombinant gp120BaL, gp120ZM651 and gp140AncC-mediated 
apoptosis of uninfected Jurkat T lymphocytes 
2.8.1 Maintenance of Jurkat T lymphocyte cell lines 
 
Jurkat T lymphocytes were propagated in 25cm3 flasks (Nunc, Roskilde, Denmark) 
while being maintained in complete RPMI-1640 (Sigma-Aldrich; Steinheim, 
Germany), [RPMI-1640 supplemented with 10% heat-inactivated FCS, L- glutamine 
(200nM), Penicillin (1000µg/ml) and streptomycin (1000µg/ml)] (Appendix A.2). When 
viable Jurkat T lymphocyte densities were above 1x106cells/ml, the lymphocytes were 
diluted and re-seeded at 2x105cells/ml. Briefly, suspension Jurkat T lymphocytes 
were gently vortexed to disperse clumps, and the appropriate volumes of 
lymphocytes were subsequently transferred into new 25cm3 flasks and made up to 
10ml with fresh complete RPMI-1640 media. 
2.8.2 Jurkat T lymphocyte stocks and cell counting 
 
Jurkat T lymphocyte stocks were prepared in a filter sterilised freezing mix (Appendix 
A.2). The lymphocytes were centrifuged at 200xg for 10 minutes and subsequently 
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resuspended in freezing mix, ensuring that there was 1x106 cells/ml. The protocol 
hereafter was performed in the exact same manner as mentioned in section 2.3.1.1. 
Jurkat T lymphocyte cell lines were discarded after 20 passages, and new cell lines 
were propagated from frozen cell stocks. Jurkat T lymphocytes were counted using 
trypan blue solution on a haemocytometer as explained in section 2.3.1.2.    
2.8.3 Establishment of a flow cytometric protocol for the analysis of early and 
late apoptosis of Jurkat T lymphocytes by Annexin V and 7-AAD staining 
 
The Cytomics FC500 (Beckman Coulter) five colour flow cytometer was used in all 
flow cytometric analyses. The machine was calibrated daily with fluorescently labeled 
beads (Beckman Coulter Inc, Fullerton, CA, USA) to ensure that the lasers were 
aligned properly, and washed appropriately after use, as per training instructions. 
Choosing the relevant parameters, a protocol to measure early and late apoptosis in 
Jurkat T lymphocytes using Annexin V and 7-amino-Actinomycin D (7-AAD) staining 
was established and optimized. The FL1 channel was used for the detection of 
Annexin V-FITC while 7-AAD was detected in the FL4 channel. Therefore, the 
protocol included a forward scatter (FSC) (measures cell size) versus side scatter 
(SSC) (measures cell granularity/complexity) dot plot to visualise and characterise the 
entire population of Jurkat T lymphocytes, an Annexin V versus 7-AAD dot plot, and 
corresponding histograms for the analysis of Annexin V and 7-AAD staining.  The 
appropriate channels and voltages were established by positioning the viable Jurkat T 
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lymphocytes in the correct quadrant for the dot plot (which measure 2 parameters) 
and to ensure that the negative peaks in the histograms (which measure 1 parameter) 
were within the first decade. Ultimately, the total number of events acquired for 200 
seconds was used as the cut off, and these settings were kept constant in all flow 
cytometric protocols. 
 
Untreated and 4µM Camptothecin (Sigma-Aldrich, Steinheim, Germany) (pro-
apoptotic agent used as a positive control)-treated Jurkat T lymphocytes 
(1x106cells/ml) were processed in order to establish baselines to which the 
recombinant Env glycoprotein-treated samples would be compared. Camptothecin is 
a highly toxic chemical compound that induces apoptosis in a dose dependent 
manner by inhibiting the DNA topoisomerase I enzyme during DNA synthesis [256, 
257]. 
2.8.4 Flow Cytometric analysis of early and late apoptosis 
 
Initially, apoptosis experiments were established using only recombinant gp120BaL 
and gp120ZM651. Jurkat T lymphocytes (1x106cells/ml) were seeded in a 24-welled 
plate (Nunc, Roskilde, Denmark) and either untreated (negative control) or treated 
with 4µM Camptothecin (Appendix A.8), 50nM of recombinant gp120BaL or gp120ZM651 
and incubated in a water jacketed 37°C, 5% CO2 incubator until sampled. Samples 
(500µl) were taken at 0 (baseline), 24 and 48 hours. For each batch of samples at 
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different time points, an untreated stained, 4µM Camptothecin-treated, gp120BaL and 
gp120ZM651-treated samples were analysed by Annexin V and 7-AAD staining. 
2.8.4.1 Annexin V and 7-AAD staining 
 
The Annexin V-FITC/7-AAD kit (Beckman Coulter Inc, Fullerton, CA, USA) was used 
to measure early and late apoptosis (2 parameters), according to manufacturers’ 
instructions. A cell that is undergoing early apoptosis is physiolocially different to a 
cell that is undergoing late apoptosis. Early apoptosis is characterised by externalised 
phosphotidyl serine residues in the phospholipid bilayer of the cell membrane while 
late apoptosis is characterised by DNA fragmentation and the formation of apoptotic 
bodies [258, 259].  Annexin V is a calcium-dependent phospholipid binding protein 
that is able to detect these phosphotidyl serine residues [258, 259], which can be 
fluorescently labeled with Annexin V that is conjugated to FITC. Seven-AAD on the 
other hand, is a fluorescent dye that is able to pass through cell membranes that have 
lost their integrity and structure and stain nucleic acids [260]. When used together, 
Annexin V and 7-AAD staining can be analysed simultaneously to detect early and 
late apoptosis/necrosis [260]. Jurkat T lymphocytes that stain positive for Annexin V 
only (Ann V+/7-AAD-) are undergoing early apoptosis while, those that stain positive 
for both Annexin V and 7-AAD (Ann V+/7-AAD+) are undergoing late apoptosis and 
possibly early necrosis. Viable Jurkat T lymphocytes stain negative for both Annexin 
V and 7-AAD (Ann V-/7-AAD-) and the completely necrotic lymphocytes stain positive 
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for 7-AAD only (Ann V-/7-AAD+). The analysis of early and late apoptosis assisted in 
defining and understanding the physical cellular state of the treated lymphocytes at 
the various timepoints used. 
 
The 10X binding buffer (Appendix A.8) provided within the Annexin V-FITC/7-AAD kit 
was diluted 10 times in sH2O, stored at 4°C and used in all subsequent staining 
procedures. For each time point, the samples were centrifuged at 500xg for 5 
minutes, resuspended in 100µl of 1X binding buffer, and dual stained on ice with 10µl 
Annexin V-FITC and 20µl 7-AAD. Samples were left on ice in the dark for 15 minutes, 
followed by the addition of 400µl of 1X binding buffer. Finally, the samples were 
analysed by flow cytometry within an hour of staining. These experiments were 
performed several times to ensure consistency and representative data from a single 
experiment is shown later in the study. 
 
The experiment was repeated using the same controls but different concentrations of 
gp120BaL and gp120ZM651. Instead of using 50nM gp120BaL and gp120ZM651, 
concentrations of 250nM and 500nM were used, to determine if gp120BaL and 
gp120ZM651-mediated apoptosis occurred in a dose/concentration-dependent manner.  
 
Furthermore, the flow cytometric protocol was modified by the addition of a dot plot 
that measured CD4 expression on the Jurkat T lymphocytes (CD4-PE versus SSC). 
This was to ensure that at least 80-90% of the Jurkat T lymphocytes were CD4 
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positive. The dot plot and histograms displaying Annexin V/7-AAD staining was gated 
on the CD4+ Jurkat T lymphocyte population. The staining procedures were 
performed as mentioned in section 2.8.3.1 with an addition of a CD4-PE antibody 
which was detected in the FL2 channel.  
 
The modified protocol was used for Annexin V/7-AAD analysis of 50nM recombinant 
gp120BaL, gp120ZM651 and gp140AncC-mediated apoptosis. The experiment was 
established in the same manner described in section 2.8.3 and an additional negative 
control (mock) was used. The mock control was prepared and purified from the 
supernatant of HEK293T cells transfected with an empty plasmid.This experiment 
was performed at least three times to ensure consistency and representative data 
from a single experiment is shown later in the study. In addition to Annexin V and 7-
AAD analysis, the Jurkat T lymphocytes were subjected to TUNEL for the detection of 
chromosomal DNA fragmentation. 
2.8.4.2 DNA fragmentation detection by Tdt-mediated dUTP Nick End 
Labeling (TUNEL) 
 
DNA fragmentation was detected and quantified using the DeadEndTM Fluorometric 
TUNEL System (Promega Corporation, Madison, USA) according to the 
manufacturer’s instructions (Technical Bulletin #TB235 at www.promega.com/tbs). 
The TUNEL assay measures DNA fragmentation which is a hallmark of late 
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apoptosis. The assay is based on the action of Terminal deoxynucleotidyl transferase 
(Tdt) enzyme, which functions by adding Fluorescein (FITC)-labelled-2’-deoxyuridine 
5’- triphosphates (FITC-dUTPs) to the exposed 3’ hydroxyl ends of the fragmented 
DNA [261, 262].   
 
As with the Annexin V/7-AAD staining analysis, a protocol was set up and optimised 
for the TUNEL assay using untreated (negative control) or 4µM Camptothecin-treated 
Jurkat T lymphocytes. The protocol established was similar to that of the Annexin V 
and 7-AAD protocol, including a FSC versus SSC dot plot, a CD4-PE versus SSC dot 
plot (gating around CD4+ Jurkat T lymphocytes), and a histogram that measured 
TUNEL-FITC activity (DNA fragmentation). TUNEL activity was detected in the FL1 
channel and the histogram was gated on the CD4+ Jurkat T lymphocytes therefore 
demonstrating apoptosis of CD4+ Jurkat T lymphocytes only.  
 
Jurkat T lymphocytes (2x106cells/ml) were untreated, 4µM Camptothecin-treated, 
50nM of recombinant gp120BaL, gp120ZM651 or gp140AncC-treated, or mock-treated and 
incubated in a water jacketed 37°C, 5% CO2 incubator until sampled at 0 and 65 
hours post treatment. Initially, the TUNEL experiments were performed at 0, 24, 48, 
65 hours as done previously by Arthos et al, 2002 on gp120-treated PBMCs [227] and 
72 hours to determine the timepoint at which efficient levels of DNA fragmentation 
could be observed. Efficient levels of DNA fragmentation were observed post 48 
hours, and it was found that apoptotic levels could be more easily measured at 65 
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hours compared to those observed at 72 hours (data not shown). Samples (1ml) were 
transferred into a 15ml tube (Nunc, Roskilde, Denmark) and washed twice with 1ml of 
1X PBS by centrifuging at 300xg for 10 minutes at 4ºC in order to remove the FCS 
from the lymphocytes, as the serum is able to inactivate the Paraformaldehyde fixing 
regent. The pellets were resuspended in 500µl of 1X PBS and 5ml of 1% 
Paraformaldehyde (BDH Limited Poole, England) (Appendix A.8) before being 
incubated for 20 minutes on ice. Each sample was washed once with 1ml of 1X PBS 
by centrifuging at 300xg for 10 minutes at 4ºC and resuspended in 500µl of 1X PBS. 
The lymphocyte membranes were permeabilized overnight with 5ml of 70% ethanol 
(Appendix A.1) at -20ºC.  
 
Thereafter, the lymphocytes were washed twice with 1ml of 1X PBS by centrifuging at 
300xg for 10 minutes at 4ºC and during the wash, a 50µl Tdt enzyme solution (1µl of 
Tdt enzyme, 5µl of Nucleotide mix and 45µl of Equilibration buffer) was prepared 
according to the manufacturers’ instructions. The pellets were equilibrated with the 
equilibration buffer (provided in the kit) for 5 minutes at room temperature before 
being centrifuged at 300xg for 10 minutes at 4ºC. Thereafter, the Tdt enzyme solution 
was added to the pellet and incubated at 37ºC in a water bath for one hour with 
minimal light exposure. The reactions were gently resuspended every 15 minutes.  
After the one hour incubation, 1ml of 1X PBS containing 20mM EDTA (Appendix A.8) 
was added, and the sample was vortexed gently followed by centrifugation at 300xg 
for 10 minutes at 4ºC. The pellets were then washed in 1ml of 1X PBS-BSA 
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containing 0.1% Triton-100 (Appendix A.8) by centrifuging again at 300xg for 10 
minutes at 4ºC. After resuspending the lymphocytes in 100µl of 1X PBS they were 
stained with 10µl of the CD4-PE monoclonal antibody for 15 minutes in the dark at 
room temperature. Finally, 400µl of 1X PBS was added to the stained cells and all the 
samples were analysed by flow cytometry within an hour of staining. This experiment 
was performed at least three times to ensure consistency and data from a single 
experiment are subsequently shown.  
2.9 Recombinant gp120BaL, gp120ZM651 and gp140AncC-mediated 
apoptosis of uninfected CD4+ T lymphocytes 
2.9.1 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) and CD4+T 
lymphocytes 
 
Individual fresh HIV-1 seronegative, category C (regular donors) buffy coat blood 
samples were obtained from the SANBS for the isolation of PBMCs and CD4-
enriched PBMCs (subsequently referred to as CD4+ T lymphocytes). All experiments 
were performed using single donor buffy preparations. For the isolation of CD4+ T 
lymphocytes, each buffy coat (10ml) was diluted in an equal volume (10ml) of 1X PBS 
containing 2% FCS (PBS-FCS) (Appendix A.7) after being incubated with the Human 
CD8+ Cell Depletion cocktail (Rosettesep; Stem Cell Technologies Inc, Catalog 
Number: 15663) for 20 minutes at room temperature, according to the manufacturer’s 
instructions. The diluted blood was then divided in half and very gently layered onto 
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15ml of Ficoll-PaqueTM Plus (GE Healthcare Biosciences) within 50ml tubes (Nunc, 
Roskilde, Denmark). The samples were centrifuged at 350xg for 30 minutes at room 
temperature and the buffy layer which contained the CD4+T lymphocytes was 
removed. The CD4+T lymphocytes were washed 3-5 times in PBS-FCS by 
centrifugation at 230xg for 10 minutes at room temperature. The supernatant was 
discarded each time while the pellet was resuspended in PBS-FCS before every 
subsequent wash. Finally, the CD4+ T lymphocytes were resuspended in 5ml of 
complete RPMI-1640 medium, counted and seeded. The isolation of PBMCs was 
performed in the same manner except that the Human CD8+ Cell Depletion cocktail 
was not used. Although the culture looked fairly pure, we cannot exclude the 
possibility of monocytes, but as seen during flow cytometric analyses where 
monocytes, which have a different physiological appearance, would appear as a 
separate population, majority of monocytes have been excluded. Furthermore, the 
purity of each enriched fraction was assessed by CD8-ECD staining by flow 
cytometry, ensuring that more than 95% of the isolated and enriched fraction was 
CD4 positive only (data not shown). 
2.9.2 Counting and maintenance of PBMCs and CD4+T lymphocytes 
 
PBMCs and CD4+T lymphocytes were counted using trypan blue solution on a 
haemocytometer as explained in section 2.3.1.2 and 2x106 cells were seeded in a 
75cm3 culture flask and stimulated with Phytohaemagglutinin Phaseolus vulgaris 
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(PHA-P) (Sigma-Aldrich, Steinheim, Germany) at a concentration of 1µg/ml. Human 
Interleukin-2 (hIL-2) (Roche; Mannheim, Germany) was added to the lymphocytes 24 
hours later at a concentration of 50U/ml. After 48 hours of hIL-2 stimulation and 72 
hours of PHA treatment, the lymphocytes were ready for use in the apoptosis assays 
as discussed later and thereafter maintained in complete RPMI-1640 medium 
(Appendix A.2) containing 10U/ml of hIL-2 in a water jacketed 37ºC, 5% CO2 
incubator. This protocol is used routinely in our laboratory. Furthermore, previous 
work in our laboratory has established that this protocol results in activated 
lymphocytes. Therefore an activation marker was not used each time the experiment 
was repeated.  
 
The culture flask was incubated in an upright position causing the lymphocytes to 
settle down at the bottom of the flask. The lymphocytes were not split or diluted, but 
replenished with fresh complete RPMI-1640 medium by either centrifuging the 
lymphocytes at 250xg for 5 minutes at 4ºC and resuspending in complete RPMI-1640 
medium containing 10U/ml of hIL-2, or by simply removing a small volume of the old 
media and replacing it with fresh complete RPMI-1640 media containing 10U/ml of 
hIL-2. This was performed every 2-3 days and lymphocytes were discarded after 2 
weeks.  
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2.9.3 The comparison of recombinant gp120-mediated apoptosis of activated 
PBMCs and CD4+ T lymphocytes 
2.9.3.1 Establishment of a flow cytometric protocol for the analysis of early 
and late apoptosis by Annexin V and 7-AAD staining 
 
The establishment of a protocol to measure early and late apoptosis of activated 
PBMCs and CD4+T lymphocytes was setup in a similar manner as for the Jurkat T 
lymphocytes. The protocol demonstrated apoptosis of CD3+CD4+ PBMCs/T 
lymphocytes. The FL1 channel was used for the detection of Annexin V-FITC, the 
FL2 channel was used for the detection of the CD4-PE, the FL3 channel was used for 
the detection of the CD8-ECD antibody, the FL4 channel was used for the detection 
of 7-AAD and the FL5 channel was used for the detection of the CD3-PC7 antibody. 
The protocol included a FSC versus SSC dot plot, a CD3-PC7 versus CD4-PE dot 
plot containing a gate around the CD3+CD4+ T lymphocytes, an Annexin V versus 7-
AAD dot plot and an histogram measuring CD8-ECD staining, both of which were 
gated on the CD3+CD4+ T lymphocytes. Untreated and 4µM Camptothecin-treated 
PBMCs/CD4+T lymphocytes (1x106/ml) were processed in order to establish 
baselines which the treated samples were compared to.  
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2.9.3.2 Flow cytometric analysis of early and late apoptosis using Annexin 
V/7-AAD staining 
 
Both activated PBMCs and CD4+ T lymphocytes were analysed and compared to 
allow for an optimal protocol set-up, and to determine which cell types allowed for 
optimal detection of gp120 mediated apoptotic events. For this comparison, only one 
of the purified recombinant Env glycoproteins (gp120BaL) was used. Therefore, after 
48 hours of hIL-2 stimulation and 72 hours of PHA treatment, the activated 
lymphocytes were untreated, 50nM gp120BaL-treated, 4µM Camptothecin-treated and 
mock-treated. Samples were taken at 0, 5, 24 and 48 hours and the levels of early 
and late apoptosis were analysed by CD3-PC7, CD4-PE and Annexin V/7-AAD 
staining. The staining procedures were performed as mentioned in section 2.8.3.1 
with an addition of 10µl of the CD4-PE and CD3-PC7 antibodies which were detected 
in the FL2 and FL5 channels, respectively. This experiment was performed once in 
duplicate and data from a single experiment is shown. 
2.9.4 The analysis of early and late apoptosis of gp120BaL, gp120ZM651 and 
gp140AncC-treated CD4+T lymphocytes 
 
After 48 hours of hIL-2 stimulation and 72 hours of PHA treatment, the activated 
CD4+T lymphocytes (1x106cells/ml) were seeded in a 24-well plate (Nunc) and either 
untreated (negative control) or treated with 4µM Camptothecin, the mock purification 
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control, 50nM of either recombinant gp120BaL, gp120ZM651 or gp140AncC and incubated 
in a water jacketed 37°C, 5% CO2 incubator until sampled. Samples (500µl) were 
taken at 0 (baseline), 24 and 48 hours. All samples at each time point were analysed 
by Annexin V and 7-AAD staining as mentioned in 2.8.3.1 with the addition of 10µl of 
the CD4-PE, CD3-PC7 and CD8-ECD antibodies which were detected in the FL2, 
FL5 and FL3 channels, respectively. This experiment was performed three times to 
ensure consistency and data from a single experiment is shown. 
2.9.5 Detection of DNA fragmentation of gp120BaL, gp120ZM651 and gp140AncC-
treated CD4+T lymphocytes by TUNEL 
 
The establishment of a protocol that measured DNA fragmentation within treated 
CD4+T lymphocytes was set up in a similar manner as the Annexin V and 7-AAD 
staining analysis protocol. The protocol included a FSC versus SSC dot plot, a CD3-
PC7 versus CD4-PE dot plot gating around the CD3+CD4+ T lymphocytes and 
histograms measuring CD8-ECD staining (for the detection of CD8-ECD positive 
lymphocytes) and TUNEL-FITC activity both of which were gated on the CD3+CD4+ 
T lymphocyte. The experiment was established as mentioned in section 2.9.4. 
Samples were taken at 0 hours and 65 hours post treatment and the difference was 
analysed by TUNEL as mentioned in section 2.8.3.2 with the addition of 10µl of the 
CD3-PC7 and CD8-ECD antibodies. This experiment was performed three times to 
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ensure consistency to ensure consistency and representative data from a single 
experiment is shown later in the study.  
2.10 Presentation and analysis of flow cytometry data 
 
All dot plots generated were analysed using the quadstats feature offered in the CXP 
2.2 software on the Cytomics FC500. The data (represented as percentages within 
each quadrant) obtained from the Annexin V and 7-AAD staining analysis of early and 
late apoptosis of untreated, 4µM Camptothecin-treated, mock-treated, gp120BaL, 
gp120ZM651 and gp140AncC-treated Jurkat and CD4+ T lymphocytes were analysed 
relative to the baseline values (untreated control) obtained. The difference in 
percentage between the untreated samples and treated samples at 24 and 48 hours 
post treatment were presented in the format of Tables. The data presented for each 
cell type was taken from one experiment. The levels of DNA fragmentation obtained 
from the TUNEL assays performed on the untreated, 4µM Camptothecin-treated, 
mock-treated, gp120BaL, gp120ZM651 and gp140AncC-treated Jurkat and CD4+ T 
lymphocytes were displayed as percentages on histograms and analysed relative to 
the baseline values (untreated control) at the two time points tested. The data 
presented for each cell type was taken from one experiment. 
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CHAPTER 3: RESULTS 
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3.1 Recombinant gp120BaL, gp120ZM651 and gp140AncC expression, 
purification and characterization 
3.1.1 Large scale plasmid preparation of gp120BaL, gp120ZM651 and gp140AncC 
recombinant expression plasmids 
 
Single colonies of recombinant E.coli DH5α transformed with gp120BaL, gp120ZM651 
and gp140AncC were grown overnight and successfully used to extract sufficient 
quantities and qualities of each plasmid (Figure 3.1). The three purified plasmids were 
used in transfection experiments of HEK 293T mammalian cells and were isolated 
throughout the study, as required. In addition, the pcDNA 3.1 expression plasmid 
(with no inserts) was obtained for use in control transfections, and mock purifications. 
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Figure 3.1: Agarose gel electrophoresis (0.8%) of (A) recombinant pciNeo-BaLgp120 (BaL), 
p96ZM651gp120-CD5-opt (Zm) and (B) Ancestral subtype C gp140 (AncC) expression 
plasmids extracted from recombinant E.coli DH5α. DNA sizes (bp - base pairs) are indicated 
on the left. Mw: O’ GeneRulerTM DNA ladder mix (range 50bp-10kb) (Fermentas), M: empty 
pcDNA 3.1 expression plasmid (mock). 
  
3.1.2 Optimization of HEK 293T mammalian transfections 
 
Comparison of the two different transfection protocols (Polyfect versus Calcium 
Chloride) showed that expression of gp120ZM651 and gp120BaL in HEK 293T 
mammalian cells was more efficient with the Polyfect® reagent at 24, 48 and 72 
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hours post transfection (Figure 3.2A and B). It appeared that there was no or minimal 
expression of gp120BaL with the calcium chloride protocol (Figure 3.2B). 
  
The non specific bands seen in Figure 3.2A and B are as a result of pooled HIV-1 
seropositive human sera that were used as the primary antibody in the western blot 
analysis. 
 
Thus, the Polyfect method was used in all subsequent transfection experiments, and 
supernatants were harvested at 48 hours post transfection. This is the established 
method used in our laboratory for the expression of gp140AncC   (Figure 3.2C), thus all 
three Env glycoproteins were expressed using transient transfections of HEK 293T 
mammalian cells with recombinant DNA and the Polyfect® reagent.     
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Figure 3.2: Western blot comparison of harvested supernatants from (A) Polyfect and (B) CaCl2 transfections of HEK 293T cells 
with gp120BaL (BaL) and gp120ZM651 (Zm) at 24 (Zm24, BaL24), 48 (Zm48, BaL48) and 72 (Zm72, BaL72) hours post transfection and 
(C) Polyfect transfections of HEK 293T cells with gp120AncC at 24 (Anc24) and 48 (Anc28) hours post transfection. Mw: Protein 
Molecular weight marker, broad range (6-175 kilodaltons;kDa) (Biolabs, New England), PC: HIV-196ZM651gp120 (NIH) Positive 
Control, NC: Negative control, supernatant harvested from non transfected HEK 293 T cells at 72 hours, M:Polyfect transfections 
of mock plasmid at 48 hours post transfection. Protein sizes (kDa; kilodaltons) are indicated on the left. 
PCMw M Anc
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3.1.3 Purification of gp120BaL, gp120ZM651 and gp140AncC by lectin affinity 
chromatography 
 
Recombinant gp120BaL, gp120ZM651 and gp140AncC were successfully expressed on a 
large scale in HEK 293T cells, and purified by lectin affinity chromatography. The 
expression and purification procedures of gp120BaL and gp120ZM651 were analysed by 
SDS-PAGE and Western Blotting. 
 
There was no unbound protein present in the harvested supernatants and washing 
buffers after being passed through the lectin column as seen in lanes FT and W of the 
recombinant gp140AncC purification process (Figure 3.3A and B). The same result was 
observed in the SDS-PAGE and Western Blot analysis of the purification processes of 
recombinant gp120BaL and gp120ZM651 (results not shown). All three purified and 
concentrated recombinant Env glycoproteins did not appear to be degraded as seen 
in Figure 3.3E, and were of the expected sizes of 120kDa (gp120BaL and gp120ZM651) 
and 140kDa (gp140AncC). 
  
The non-specific bands that are visible on the Western blot (left) of the mock 
purification process (Figure 3.3C) could be other cellular proteins that are detected by 
the human sera primary antibody used during Western Blot analysis. 
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Figure 3.3: SDS-PAGE (on the right) and Western Blot analysis (on the left) of the recombinant gp140AncCprotein (A and B) and 
mock (C and D) purification procedures. (E) SDS-PAGE and Coomassie Brilliant Blue staining analysis of all three purified and 
concentrated recombinant proteins. PM: Molecular weight marker, broad range (6-175 kilodaltons;kDa) (Biolabs), IP: Input, FT: 
Flow through, W: Wash, EL: Elution, CN: Concentrated recombinant protein, PC: HIV-196ZM651gp120 (NIH) Positive Control. Protein 
sizes (kDa) are indicated on the left. 
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3.1.4 Quantification of purified recombinant gp120BaL, gp120ZM651 and 
gp140AncC 
 
A standard curve was obtained using the absorbance readings obtained from 
standard concentrations of BSA protein (Figure 3.4). The straight line equation 
(y=0.0019x+0.1134) was used to determine the concentration of the protein by 
solving for the x-value. The y-value is the mean absorbance value and the R2-value 
represents how well the straight line is fitted to each point of the graph. Therefore, a 
higher R2 –value means a better or closer fit of each absorbance value (point) to the 
straight line graph. For the initial purifications, the concentrations of gp120BaL, 
gp120ZM651 and gp140AncC were 107.6µg/ml, 162.5µg/ml and 150µg/ml, respectively. 
These concentrations varied in subsequent purifications, but, overall, approximately 
2mg of recombinant gp120BaL and gp140AncC was purified from 2L of harvested 
supernatant, while 1.5mg of recombinant gp120ZM651 was purified from 2L of 
harvested supernatant.  
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Figure 3.4: Typical standard curve graph obtained from a range of BSA concentrations. The 
straight line equation and R2 value is shown on the top right corner.  
 
3.1.5 Characterization of purified recombinant gp120BaL, gp120ZM651 and 
gp140AncC 
 
Conformational studies were successfully performed on the expressed, purified and 
concentrated Env glycoproteins to determine that they were conformationally intact as 
well as functional (Figure 3.5). The binding efficiency of recombinant gp120ZM651, 
gp120BaL and gp140AncC to Mabs IgG1b12, 17b, 17b post sCD4 binding, 48D and 
2G12 was analysed. These Mabs bind to functionally and structurally important 
epitopes on gp120 (see discussion). The data shown in Figure 3.5 represents the 
means from duplicate analyses of single parameters which are the different 
antibodies that were used.  
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Recombinant gp120ZM651, gp120BaL and gp140AncC were all able to bind the MAb 
IgG1b12 (Figures 3.5A-C), in a dose dependent manner. There were differences 
noted between binding of gp120ZM651, gp120BaL and gp140AncC to 17b, 17b post sCD4 
binding and 2G12 (Figures 3.5A-C). For example, only gp120BaL could bind 2G12 
(Figures 3.5A-C). In addition, 17b was only able to bind recombinant gp120BaL and 
gp140AncC in the presence of sCD4 (Figures 3.5B and C). 
 
Because the capture ELISA did not show gp120ZM651 binding to 17b in the presence 
of sCD4, (which is an indirect measure of gp120-sCD4 binding), a further CD4 
binding ELISA was performed (Figure 3.6). The data shown in Figure 3.6 represents 
the means from duplicate analyses of single parameters (48D in the presence and 
absence of CD4). 
 
Results showed that in the presence of full length sCD4, 48D interacted very 
poorly/not at all with gp120ZM651 and gp140AncC , but strongly with gp120BaL (Figures 
3.6A, B and C)    
   
Even though gp120ZM651 was unable to interact with 17b, it did however show efficient 
binding affinities for IgG1b12, whose epitopes overlap with the CD4 binding site. 
Overall, all three recombinant Env glycoproteins had a functional CD4 binding site, 
and were conformationally intact, and were used for all subsequent experiments. 
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Figure 3.5: The measurement of antibody binding to purified recombinant HIV-1 gp120ZM651 
(A), gp120BaL (B) and gp140AncC (C) by capture ELISAs. Error bars represent standard 
deviation. 
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Figure 3.6: Bar charts depicting the ability of purified recombinant HIV-1 gp120BaL (A), 
gp120ZM651 (B), gp140AncC (C) and HIV-196ZM651gp120 (NIH) (D) to interact with 48D in the 
presence of full length sCD4. Error bars represent standard deviation. 
 
 
All three recombinant Env glycoproteins were then analysed for their ability to induce 
apoptosis of Jurkat T lymphocytes via gp120-CD4 interactions and of CD4+ T 
lymphocytes via gp120-CD4 and/ or co-receptor interactions (CCR5 in this case). 
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3.2 Flow cytometric analyses of gp120BaL, gp120ZM651 and 
gp140AncC-mediated early and late apoptosis of uninfected 
Jurkat T lymphocytes 
 
All the flow cytometry experiments were performed several times, and dot plots 
and/or histograms and associated tables from only one experiment that was 
considered representative of the data is depicted throughout.   
3.2.1 Establishment of a flow cytometric protocol for the analysis of Annexin V 
and 7-AAD staining of uninfected Jurkat T lymphocytes   
A protocol that could measure early and late apoptosis using Annexin V and 7-AAD 
staining was successfully established using untreated Jurkat T lymphocytes (Figure 
3.7). The untreated lymphocytes were stained with Annexin V and 7-AAD, and the 
typical analysis plots selected and incorporated into the protocol (shown for each 
experimental run) included a forward scatter linear (FSC) and side scatter log (SSC) 
dot plot confirming the entire Jurkat T lymphocyte population (Figure 3.7A), and an 
ungated Annexin V versus 7-AAD dot plot showing the proportions of Jurkat T 
lymphocytes staining positive for either or both markers (Figure 3.7B). In the example 
shown in Figure 3.7B, the majority of Jurkat T lymphocytes were viable (94.8%; 
stained negative for both Annexin V and 7-AAD in quadrant A3), while 4.0% and 1.1% 
were undergoing early (Annexin V positive; quadrant A4) and late apoptosis (Annexin 
V and 7-AAD positive; quadrant A2), respectively. Completely necrotic Jurkat T 
 81 
lymphocytes were detected in quadrant A1 (0.2%; 7-AAD positive). The ungated 
histograms in Figures 3.7C and 3.7D represent the total percentage of lymphocytes 
that stained positive for Annexin V and 7-AAD, respectively.  Recombinant gp120BaL 
and gp120ZM651 were chosen for the establishment and optimization of the Annexin V 
and 7-AAD staining assay.  The flow cytometry protocol outlay shown in Figure 3.7 
was used initially for the analysis of early and late apoptosis of gp120BaL and 
gp120ZM651-treated (using concentrations of 50nM, 250nM or 500nM) and untreated 
Jurkat T lymphocytes.  
 
(A)
( )C (D)
(B)
 
Figure 3.7: Example of Dot blots and histograms of untreated lymphocytes from the protocol 
established for the Annexin V and 7-AAD staining analysis of gp120BaL and gp120ZM651-
mediated early and late apoptosis of Jurkat T lymphocytes. The entire cell population is 
shown in (A), and the viable cells are positioned within the first decade (100), as seen in (B), 
(C) and (D).   
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3.2.2 Early and late apoptosis of uninfected Jurkat T lymphocytes mediated by 
varying concentrations of gp120BaL and gp120ZM651 
 
Data from the results obtained are shown in Figure 3.8, displaying the outcome of the 
staining analysis of untreated and Camptothecin-treated Jurkat T lymphocytes at 24 
hours post treatment.  
 
Untreated Camptothecin-treated
 
Figure 3.8: Dot plots displaying the Annexin V and 7-AAD staining analysis of untreated and 
4µM Camptothecin-treated Jurkat T lymphocytes from one experiment at 24 hours post 
treatment. 
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3.2.2.1 Apoptosis of Jurkat T lymphocytes mediated by 50nM, 250nM and 
500nM gp120BaL and gp120ZM651 
 
The ability of 4µM Camptothecin (positive control), 50nM gp120BaL and gp120ZM651 to 
induce apoptosis of Jurkat T lymphocytes over time was analysed by Annexin V and 
7-AAD staining. The results from a single experiment are presented in Table 3.1. The 
percentages obtained in the quadrants for early (A4) and late (A2) apoptosis at 24 
and 48 hours post treatment were subtracted from the untreated/baseline percentage 
values at the same time points and the differences are shown in Table 3.1. As 
expected, relative to the baseline, the Camptothecin positive control induced high 
levels of late apoptosis (22%) 24 hours post treatment, with 60% of the Jurkat T 
lymphocyte population undergoing late apoptosis and entering necrosis at 48 hours 
post treatment (Table 3.1).  
 
Furthermore, the addition of 50nM gp120BaL and gp120ZM651 induced low levels (less 
than 10%) of late apoptosis over time, with 6.9% and 1.9% of gp120BaL and 
gp120ZM651-treated Jurkat T lymphocytes expressing late apoptosis markers at 48 
hours post treatment, respectively (Table 3.1). There were higher levels of early 
apoptosis after 24 and 48 hours of exposure to 50nM gp120ZM651 in comparison to 
50nM gp120BaL. However, gp120BaL induced the highest levels of late apoptosis after 
48 hours of exposure (Table 3.1). Overall, 50nM gp120BaL and gp120ZM651-treated 
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Jurkat T lymphocytes displayed low levels of early and late apoptosis after 48 hours 
of treatment. 
 
Table 3.1: Percentages of early and late apoptosis of Jurkat T lymphocytes from 
individual experiments mediated by 50nM, 250nM and 500nM gp120BaLand 
gp120ZM651 at 24 and 48 hours post exposure. 
 
 
Lymphocyte Treatments 
(Jurkat T lymphocytes) 
 
Percentage of Early 
Apoptosis  
(Ann V+/7-AAD-) 
(%) 
 
Percentage of Late 
Apoptosis  
(Ann V+/7-AAD+) 
(%) 
 24 hours  48 hours  24 hours  48 hours  
     
4µM Camptothecin 19.8 2.6 22.0 60.0 
Untreated 2.2 3.9 2.0 4.3 
50nM gp120ZM651 1.2 1.0 0.7 1.9 
Untreated 3.0 1.5 2.3 2.5 
250nM gp120ZM651 1.6 1.6 - 0.4 
500nM gp120ZM651 - 3.9 0.3 - 
Untreated 2.2 3.9 2.0 4.3 
50nM gp120BaL - 0.4 0.9 6.9 
Untreated 3.0 1.5 2.3 2.5 
250nM gp120BaL - 7.4 1.7 2.2 
500nM gp120BaL - 9.3 1.5 2.5 
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Given that 50nM gp120BaL and gp120ZM651 induced low levels of apoptosis, Jurkat T 
lymphocytes were treated with 250nM and 500nM gp120BaL and gp120ZM651 to 
determine if there was a dose response effect (Table 3.1).  
 
Relative to the baseline, a small percentage of 250nM and 500nM gp120BaL-treated 
Jurkat T lymphocytes were undergoing late apoptosis (Table 3.1). At 48 hours post 
treatment, 250nM gp120ZM651 induced 1.6% of early apoptosis while 500nM 
gp120ZM651 induced 3.9% early apoptosis. Even though there seems to be a 
concentration effect on early apoptosis at 48 hours post exposure, both 
concentrations (250nM and 500nM) of gp120ZM651 used were unable to induce 
increased  levels of late apoptosis at this same time point (Table 3.1).  
 
Similarly, gp120BaL seemed to induce a concentration effect on the levels of early 
apoptosis after 48 hours of exposure i.e. the addition of 250nM gp120BaL induced up 
to 7.4% early apoptosis while 500nM gp120BaL induced 9.3% of early apoptosis 
(Table 3.1). Interestingly, the levels of late apoptosis induced by 250nM and 500nM 
gp120BaL after 48 hours of exposure were lower than the early levels observed at the 
same time point (Table 3.1). Furthermore, at 24 hours post treatment, 250nM 
gp120BaL was able to induce levels of late apoptosis (1.7%) that were similar to that 
induced by 500nM gp120BaL (1.5%) (Table 3.1).  
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Therefore, due to the low levels of apoptosis observed even in the presence of higher 
recombinant Env glycoprotein concentrations; 50nm gp120BaL, gp120ZM651 and 
gp140AncC was used in all subsequent experiments. In an attempt to improve the low 
levels of apoptosis being obtained, and to ensure that low levels of CD4 expression 
on the Jurkat T lymphocytes was not responsible, the established flow cytometric 
protocol was modified to confirm the presence of CD4 on the Jurkat T lymphocytes 
tested.  
 
3.2.3 Flow cytometric analysis of apoptosis mediated by 50nM gp120BaL, 
gp120ZM651 and gp140AncC using a modified protocol 
 
The settings of the previously established flow cytometric protocol were modified and 
a new protocol was set up in the exact same manner as mentioned in section 3.2.1. 
Protocol modifications included the addition of a CD4-PE versus SSC dot plot that 
measured CD4-PE staining on the Jurkat T lymphocytes (Gate C) (Figure 3.9B). The 
Annexin V versus 7-AAD dot plot (Figure 3.9C) was gated on Gate C, therefore 
displaying early and late apoptosis of CD4-PE positive Jurkat T lymphocytes only.  
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Figure 3.9: Example of dot blots of untreated lymphocytes from the modified flow cytometric 
protocol established for Annexin V and 7-AAD staining analysis of gp120BaL, gp120ZM651 and 
gp140AncC-mediated early and late apoptosis of Jurkat T lymphocytes.  
 
3.2.3.1 Early and late apoptosis mediated by 50nM gp120BaL, gp120ZM651 and 
gp140AncC  
 
Dot plots demonstrating Annexin V and 7-AAD analysis of untreated and 
Camptothecin-treated Jurkat T lymphocytes after 24 hours using the modified flow 
cytometric protocol are shown in Figure 3.10.  
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The results shown in Figure 3.11, Figure 3.12 and Table 3.2 were obtained from one 
experiment, and are representative of at least three independent experiments and 
showed comparable results (this applies to all the subsequent dot plots and 
associated Tables shown throughout the rest of the dissertation). 
 
Untreated Camptothecin-treated
 
Figure 3.10: Dot plots displaying the Annexin V and 7-AAD staining analysis of untreated and 
4µM Camptothecin-treated Jurkat T lymphocytes from one experiment post 24 hours using 
the modified protocol.  
 
In comparison to the initial protocol, the selected dot plot for the modified protocol 
showed higher levels of baseline apoptosis, and this can be attributed to a higher 
passage number of the cell lines used. Relative to the untreated Jurkat T 
lymphocytes, 50nm gp120BaL, gp120ZM651 and gp140AncC-treated Jurkat T 
lymphocytes displayed higher levels of late apoptosis at 24 hours than at 48 hours 
post treatment (Figure 3.11 and 3.12 and Table 3.2). Furthermore, relative to the 
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untreated control, the percentage of gp120BaL, gp120ZM651 and gp140AncC-treated 
Jurkat T lymphocytes undergoing early apoptosis increases (3.5%, 4.1% and 2.8%, 
respectively) with a simultaneous decrease in Jurkat T lymphocytes undergoing late 
apoptosis at 48 hours post treatment (Figure 3.12 and Table 3.2). This was not 
observed in the untreated Jurkat T lymphocytes (Figure 3.11 and Table 3.2).  
 
In addition, the mock-treated (negative control) Jurkat T lymphocytes displayed early 
and late apoptosis levels that were insignificantly higher than untreated Jurkat T 
lymphocytes (Figure 3.11 and Table 3.2). This was a consistent observation 
throughout all of the apoptosis assay experiments.  
 
Overall, these results indicate that the interaction of recombinant gp120 with CD4 is 
able to trigger low levels of apoptosis in Jurkat T lymphocytes. In addition, the 
induction of apoptosis seems to be reversible. To confirm that the Jurkat T 
lymphocytes were undergoing apoptosis, the occurrence of chromosomal DNA 
fragmentation, which is a marker of late apoptosis, was analysed.  
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Figure 3.11: Annexin V and 7-AAD analysis of untreated, mock-treated and 4µM 
Camptothecin-treated Jurkat T lymphocytes from one experiment at 24 and 48 hours post 
treatment. The Annexin V/7-AAD analysis of the untreated Jurkat T lymphocytes at 0 hours is 
included for comparative purposes.  
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Figure 3.12: Annexin V and 7-AAD analysis of 50nM gp120BaL, gp120ZM651 and gp140AncC-
treated Jurkat T lymphocytes from one experiment at 24 and 48 hours post treatment.  
 
The percentages obtained in the quadrants for early (B4) and late (B2) apoptosis of 
Jurkat T lymphocytes at 24 and 48 hours post treatment with gp120BaL, gp120ZM651 
and gp140AncC were subtracted from the untreated/baseline percentage values at the 
same time points and the differences are shown in Table 3.2. 
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Table 3.2: Percentages of early and late apoptosis of Jurkat T lymphocytes from one 
experiment mediated by 50nM gp120BaL, gp120ZM651and gp140AncC after 24 and 48 
hours of exposure. 
 
 
Lymphocyte 
Treatments 
(Jurkat T 
lymphocytes) 
 
Percentage of Early 
Apoptosis  
(Ann V+/7-AAD-) 
(%) 
 
Percentage of Late 
Apoptosis  
(Ann V+/7-AAD+) 
(%) 
 24 hours  48 hours  24 hours  48 hours  
Untreated 9.1 8.2 3.8 7.4 
     
4µM Camptothecin 2.3 8.7 59.9 61.6 
     
50nM gp120BaL - 3.5 5.7 - 
     
50nM gp120ZM651 - 4.1 3.1 - 
     
50nM gp140AncC - 2.8 3.8 - 
 
3.2.3.2 Detection of DNA fragmentation within 50nM gp120BaL, gp120ZM651 and 
gp140AncC-treated uninfected Jurkat T lymphocytes 
 
A protocol measuring chromosomal DNA fragmentation within Jurkat T lymphocytes 
using TUNEL was successfully established using untreated Jurkat T lymphocytes 
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(protocol not shown). The protocol included the same parameters as the Annexin V 
and 7-AAD staining protocol, except that the Annexin V versus 7-AAD dot plot was 
replaced with a histogram measuring TUNEL activity. The histogram was gated on 
CD4+ Jurkat T lymphocytes (protocol not shown).   
 
Untreated, 4µM Camptothecin-treated, 50nm gp120BaL, gp120ZM651, gp140AncC-treated 
and mock-treated Jurkat T lymphocytes were analyzed by TUNEL at 0 and 65 hours 
post treatment (Figure 3.13). The percentage of DNA fragmentation observed in the 
gp120BaL, gp120ZM651, gp140AncC-treated Jurkat T lymphocytes was higher than the 
untreated (6.1%, 5.0% and 6.8%, respectively) and mock-treated (4.9%, 3.8% and 
5.6%, respectively) Jurkat T lymphocytes at 65 hours post treatment (Figure 3.13). As 
expected and relative to the untreated control, Camptothecin induced DNA 
fragmentation in approximately 84.6% of the lymphocyte population (Figure 3.13).   
 
Overall, these results demonstrate low levels of DNA fragmentation that are higher 
than the levels of apoptosis obtained from the Annexin V and 7-AAD staining analysis 
(Figure 3.12 and Table 3.2), possibly due to being treated with the Env glycoproteins 
for up to 65 hours instead of 48 hours. 
 
The results shown in Figure 3.13 were obtained from one experiment, and are 
representative of at least two independent experiments that demonstrated similar 
results (this applies to subsequent TUNEL data shown later in the dissertation). 
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Figure 3.13: TUNEL analysis of DNA fragmentation in Jurkat T lymphocytes from one 
experiment induced by the addition of 50nM recombinant gp120BaL, gp120ZM651 and gp140AncC 
post 65 hours. The histogram of the untreated Jurkat T lymphocytes at 0 hours is included for 
comparative purposes. The percentage of TUNEL positive Jurkat T lymphocytes is presented 
on each histogram. The data was taken from one experiment. 
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3.3 Flow cytometric analyses of gp120BaL, gp120ZM651 and 
gp140AncC-mediated early and late apoptosis of activated CD4+ 
T lymphocytes 
3.3.1 Establishment of a flow cytometric protocol for the analysis of Annexin V 
and 7-AAD staining of activated CD4+ T lymphocytes  
 
A protocol measuring early and late apoptosis using Annexin V and 7-AAD staining 
was successfully established using untreated PBMCs and CD4-enriched PBMCs 
(subsequently called CD4+ T lymphocytes). Although the dot plots and protocol 
shown in Figure 3.14 were used for the Annexin V/7-AAD staining analysis of CD4+ T 
lymphocytes, the same parameters and settings were used for Annexin V/7-AAD 
staining analysis of PBMCs (data not shown). The entire cell population was 
confirmed in a FSC versus SSC dot plot (Figure 3.13A) and a dot plot measuring 
CD3-PC7 and CD4-PE staining was used to identify the majority CD3+CD4+ 
population (Gate H) (Figure 3.13B). The Annexin V versus 7-AAD staining dot plot 
was gated on Gate H, thereby displaying early and late apoptosis of CD3+CD4+ T 
lymphocytes only (Figure 3.14C). In addition, the depletion of CD8+ T lymphocytes 
was confirmed in a histogram measuring CD8-ECD staining (Figure 3.14D). Using 
various gating strategies, the unstained cells that produced a tail-like appearance 
around the well defined lymphocyte population in Figure 3.14B were established as 
non-specific staining through various gating strategies and were therefore not 
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included in the gate. An optimum gating strategy was used to develop optimal 
experiments. 
 
(D)( )C
(A) (B)
 
Figure 3.14: Annexin V and 7-AAD staining analysis of activated CD4+ T lymphocytes. (A) 
The entire CD8 depleted lymphocyte population, (B) the CD3-PC7 and CD4-PE positive 
lymphocytes shown in Gate H from the entire population shown in A, (C) Annexin V and 7-
AAD staining analysis of the CD3+CD4+ T lymphocytes within Gate H and (D) an histogram 
showing CD8-ECD positive T lymphocytes. The viable CD4+ T lymphocytes are positioned 
within 100 as shown in (C).  
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To determine the difference between the use of PBMCs or CD4+ T lymphocytes, both 
types were activated and treated with recombinant gp120BaL followed by the flow 
cytometric analysis of early and late apoptosis by Annexin V/7-AAD staining, using 
the established protocol (Figure 3.14). 
3.3.2 Apoptosis of PBMCs and CD4+ T lymphocytes mediated by 50nM 
gp120BaL  
 
The gp120BaL-treated PBMCs and CD4+ T lymphocytes were subjected to Annexin V 
and 7-AAD staining analysis after 5, 24 and 48 hours post treatment and levels of 
early and late apoptosis were monitored. There was no apoptosis detected in the 
gp120BaL-treated PBMCs or CD4+ T lymphocytes after 5 hours, but apoptosis levels 
increased at 24 and 48 hours post treatment, and were similar in both PBMCs and 
CD4+ T lymphocytes (results not shown). However, the dot plots and analyses were 
cleaner and more reproducible using the CD4+ T lymphocyte populations, thus, the 
CD4+ T lymphocytes were used in all subsequent apoptosis assays.  
3.3.3 Detection of early and late apoptosis of uninfected CD4+ T lymphocytes 
mediated by 50nM and 100nM gp120BaL, gp120ZM651 and gp140AncC 
 
CD4+ T lymphocytes were treated with either a 50nM or 100nM concentration of 
recombinant gp120BaL, gp120ZM651 and gp140AncC to determine if the recombinant Env 
glycoproteins would have a dose-response effect on the induction of apoptosis. Dot 
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plots from the results obtained are shown in Figure 3.15, displaying the outcome of 
the staining analysis of untreated and Camptothecin-treated CD4+ T lymphocytes 
post 24 hours (Figure 3.15).  
 
Untreated Camptothecin-treated
 
Figure 3.15: Dot plots demonstrating Annexin V and 7-AAD analysis of untreated and 4µM 
Camptothecin-treated CD4+ T lymphocytes from a single donor at 24 hours post treatment. 
 
Interestingly, all recombinant Env glycoprotein-treated CD4+ T lymphocytes retained 
their abilities to stain positive for CD3-PC7 but displayed a decrease in CD4-PE 
staining after 24 hours of treatment (Figures 3.16D-F). This could be attributed to Env 
binding to all available molecules of surface CD4, or to CD4 downregulation post 
gp120 binding. Owing to this occurrence, Gate H surrounding the CD3+CD4+ T 
lymphocytes was extended during all Annexin V and 7-AAD staining (Figure 3.16) 
and TUNEL (dot plots not shown) analyses of the gp120BaL, gp120ZM651 and 
gp140AncC-treated CD4+ T lymphocytes so to include all of the CD4+ T lymphocytes. 
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CD3-PC7 versus CD4-PE dot plots taken from the Annexin V and 7-AAD analysis 
protocol are shown in Figure 3.16, demonstrating the shift in the CD3+CD4+ T 
lymphocyte population. 
 
(A) (B) ( )C
(D) (E) (F)
 
Figure 3.16: Changes in CD4-PE binding observed in CD4+ T lymphocytes after 24 hours of 
(D) gp120BaL, (E) gp120ZM651 and (F) gp140AncC treatment which did not occur in the (A) 
untreated, (B) mock-treated and (C) Camptothecin-treated CD4+ T lymphocytes during the 
Annexin V and 7-AAD staining analyses.   
 
Relative to the baseline and after 48 hours of treatment, the 50nM concentrations of 
gp120BaL, gp120ZM651 and gp140AncC were able to induce an approximate 12.2%, 
10.3% and 14.5% increase in late apoptosis of the CD4+ T lymphocytes, respectively 
(Figure 3.18). However, the increase in concentration of all three recombinant Env 
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glycoproteins to 100nM did not produce a dose response effect. After 48 hours of 
exposure to 100nM gp120BaL, gp120ZM651 and gp140AncC, 9.7%, 7.3% and 10.4% of 
the CD4+ T lymphocytes were undergoing late apoptosis, respectively (Figure 3.19).  
 
After being exposed to Camptothecin for 48 hours, 38.1% of the CD4+ T lymphocyte 
population was undergoing late apoptosis and entering necrosis (Figure 3.17). As 
mentioned before, the mock-treated CD4+ T lymphocytes demonstrated levels of late 
apoptosis that were higher at 24 and 48 hours post treatment in comparison to the 
untreated CD4+ T lymphocytes (Figure 3.17). 
 
Overall, the results show an increase in the levels of late apoptosis in CD4+ T 
lymphocytes over time, attributed to the addition of recombinant gp120BaL, gp120ZM651 
and gp140AncC. Furthermore, higher levels of apoptosis were observed in the treated 
CD4+ T lymphocytes in comparison to the Jurkat T lymphocytes. 
 
Apoptosis of gp120BaL, gp120ZM651 and gp140AncC-treated CD4+ T lymphocytes was 
further confirmed by TUNEL analysis of chromosomal DNA fragmentation. 
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Figure 3.17: Annexin V and 7-AAD analysis of untreated, mock-treated and 4µM 
Camptothecin-treated CD4+ T lymphocytes from one donor at 24 and 48 hours post 
treatment. The Annexin V/7-AAD staining analysis of untreated CD4+ T lymphocytes at 0 
hours are included for comparative purposes. 
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Figure 3.18: Annexin V and 7-AAD analysis of 50nM gp120BaL, gp120ZM651 and gp140AncC-
treated CD4+ T lymphocytes from one donor at 24 and 48 hours post treatment.  
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Figure 3.19: Annexin V and 7-AAD analysis of 100nM gp120BaL, gp120ZM651 and gp140AncC-
treated CD4+ T lymphocytesfrom one donor at 24 and 48 hours post treatment.  
 
The percentages of early and late apoptosis post 24 and 48 hours of 50nM and 
100nM gp120BaL, gp120ZM651 and gp140AncC were subtracted from the baseline 
percentages at the same time points, and the differences are shown in Table 3.3. The 
data shown in the table are from an individual experiment that was performed using 
PBMC-derived CD4+ T lymphocytes from an individual donor. 
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Table 3.3: Percentages of early and late apoptosis of CD4+ T lymphocytes from a 
single donor mediated by 50nM and 100nM gp120BaL, gp120ZM651and gp140AncC after 
24 and 48 hours of exposure. 
 
 
Lymphocyte Treatments 
(CD4+ T lymphocytes) 
 
Percentage of Early 
Apoptosis  
(Ann V+/7-AAD-) 
(%) 
 
Percentage of Late 
Apoptosis  
(Ann V+/7-AAD+) 
(%) 
 24 hours  48 hours  24 hours  48 hours  
Untreated 10.3 10.6 9.3 10.0 
     
4µM Camptothecin 6.1 2.5 7.2 38.1 
     
50nM gp120BaL 0.8 - - 12.2 
100nM gp120BaL 0.1 - 3.7 9.7 
     
50nM gp120ZM651 - - 5.2 10.3 
100nM gp120ZM651 0.6 - 5.2 7.3 
     
50nM gp140AncC 1.2 - - 14.5 
100nM gp140AncC 2.6 1.4 - 10.4 
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3.3.4 The analysis of DNA fragmentation in 50nM gp120BaL, gp120ZM651 and 
gp140AncC-treated CD4+ T lymphocytes 
 
A protocol measuring chromosomal DNA fragmentation in untreated, 4µM 
Camptothecin-treated, mock-treated, gp120BaL, gp120ZM651 and gp140AncC-treated 
CD4+ T lymphocytes using TUNEL was successfully established using untreated 
CD4+ T lymphocytes (protocol not shown). The protocol was set up in the exact same 
manner used for the analysis of Annexin V and 7-AAD staining of CD4+ T 
lymphocytes, with the exception of a histogram, gated on CD3+CD4+ T lymphocytes, 
that measured TUNEL activity (protocol not shown). 
 
The level of DNA fragmentation in untreated and Camptothecin-treated, mock-
treated, 50nM gp120BaL, gp120ZM651 and gp140AncC-treated CD4+ T lymphocytes was 
analyzed by TUNEL after 0 and 65 hours of exposure (Figure 3.20). Relative to the 
untreated (0 and 65 hour) CD4+ T lymphocytes, gp120BaL, gp120ZM651 and gp140AncC 
induced up to 13.3%, 15.6% and 11.5% DNA fragmentation in the CD4+ T 
lymphocytes, respectively (Figure 3.20).  Camptothecin-treated CD4+ T lymphocytes 
demonstrated 50.9% of DNA fragmentation while the mock-treated CD4+ T 
lymphocytes showed a slightly higher percentage (2.1% higher) of DNA fragmentation 
in comparison to the untreated control (Figure 3.20). 
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Interestingly, the Jurkat T lymphocytes seem to be more susceptible to camptothecin 
that the CD4+ T lymphocytes. The higher susceptibility observed in the Jurkat T 
lymphocytes may be attributed to the fact that they are immortalized. Overall, in 
comparison to the Jurkat T lymphocytes, gp120BaL, gp120ZM651 and gp140AncC were 
able to induce higher levels of apoptosis of CD4+ T lymphocytes during both the 
Annexin V/7-AAD and TUNEL analyses. Furthermore, gp140AncC demonstrated the 
highest level of late apoptosis post 48 hours during the Annexin V/7-AAD analysis 
(Figure 3.18) while gp120ZM651 displayed the highest level of DNA fragmentation post 
65 hours during the TUNEL analysis (Figure 3.20).  
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Figure 3.20: TUNEL analysis of DNA fragmentation in CD4+ T lymphocytes from a single 
donor induced by the addition of gp120BaL, gp120ZM651 and gp140AncC post 65 hours. The 
histogram of the untreated CD4+ T lymphocytes at 0 hours is included for comparative 
purposes. The percentage of TUNEL positive lymphocytes is presented on each histogram. 
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CHAPTER 4: DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 107 
Apoptosis of uninfected CD4+ T lymphocytes due to aberrant signalling initiated from 
the binding of HIV-1 gp120 to the CD4 receptor as well as co-receptors, CCR5 and 
CXCR4 has been described as a contributing mechanism to the depletion of CD4+ T 
lymphocytes which in turn correlates with disease progression to AIDS [192, 219, 
263, 264]. The true mechanisms however, leading to uninfected CD4+ T lymphocyte 
death remain unclear and controversial. This study addressed the ability of 
recombinant HIV-1 gp120BaL, gp120ZM651 and gp140AncC (all CCR5-utilizing) to 
mediate apoptosis of Jurkat T lymphocytes and activated CD4+ T lymphocytes via 
interactions with CD4 only  and CD4 and/or CCR5, respectively. . 
 
The recombinant subtype B gp120BaL and subtype C gp120ZM651 and gp140AncC 
glycoproteins used throughout the course of this study were successfully expressed in 
mammalian HEK 293T cells (Figure 3.2) [265, 266], purified using lectin affinity 
chromatography (Figure 3.3) [232, 267] and quantified (Figure 3.4). Previous studies 
have employed Spodoptera frugiperda (Sf9) insect cells (baculovirus expression 
system) [255, 268, 269] and other mammalian cell lines such as Chinese hamster 
ovary (CHO) cells [83, 227, 270] for the expression of functional Env glycoproteins. 
Mammalian cell expression systems are advantageous for Env glycoprotein 
expression, as they possess the necessary machinery required for post translational 
modifications such as glycosylation, which is imperative for the stability and proper 
folding of Env glycoproteins [83, 271, 272]. The insect glycosylation pathway is 
reportedly less complex than that of mammalian cells, consequently recombinant 
gp120 expressed in insect cells has been shown to contain carbohydrates with a 
high-mannose variety compared to the more complex carbohydrates found on gp120 
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expressed in mammalian cells [273, 274]. Therefore, the expression of our 
recombinant Env glycoproteins in a mammalian cell system was expected to produce 
correctly glycosylated and folded recombinant Env glycoproteins.   
 
Expression in HEK 293T cells yielded approximately 1mg of purified gp120BaL, 
gp120ZM651 and gp140AncC per litre of culture supernatant, which was then estimated 
to be >90% pure through Coomassie Brilliant Blue staining analysis (Figure 3.3E). 
Using the same cell line and similar purification procedure, Varadarajan et al. (2005) 
were able to obtain yields of recombinant gp120 that ranged between 1-2mg per litre 
of culture supernatant [275]. Thus, the expression and purification protocol used in 
this study was relatively efficient, comparable to others and adequately addressed the 
needs of this project. 
 
The purified recombinant gp120ZM651, gp120BaL and gp140AncC Env glycoproteins were 
shown to be conformationally intact and functional in capture ELISA’s (Figure 3.5A, B 
and C, respectively), and thus used in all subsequent apoptosis experiments. The 
MAb IgG1b12 was able to bind to all three glycoproteins in a dose dependent manner 
(Figures 3.5A, B and C). These results agree with previous studies that demonstrate 
significant binding of IgG1b12 to recombinant subtype C Env glycoproteins [9], 
primary virus isolates [276, 277] as well as cross-clade reactivity [278].  MAb 
IgG1b12, is known to have a high affinity for a highly conserved epitope that overlaps 
the CD4 binding site on gp120 [279]. The V1/V2 loops of gp120 have also been 
implicated in the IgG1b12-gp120 interaction [280]. The subtype B gp120 amino acid 
residues reported to be involved in the IgG1b12-gp120 interaction include S365, 
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D368, I371, Y384 and V430 [281]. Overall, binding of all three purified recombinant 
Env glycoproteins to IgG1b12 implied that their CD4 binding sites were 
conformationally intact.   
 
Recombinant gp120BaL and gp140AncC showed enhanced binding affinities for 17b in 
the presence of sCD4 (Figures 3.5B and C) whereas extremely low binding activity 
was observed for gp120ZM651 (Figure 3.5A). The 17b epitope overlaps the V1/V2 
shielded CCR5 binding site [91, 98] and the amino acid residues that have been 
implicated in gp120 binding include K121, R419, I420, K421, Q422, I423 and Y435 
[71, 282]. Since IgG1b12 was able to bind efficiently to gp120ZM651, it can be 
suggested that the CD4 binding site of gp120ZM651 is conformationally intact, but does 
not seem to undergo the conformational rearrangements required for the exposure of 
the co-receptor binding site which includes the overlapping 17b epitope. Alternatively, 
the 17b epitope is absent on gp120ZM651.  Since gp120BaL and gp140AncC showed 
enhanced binding to 17b in the presence of sCD4, the conformational integrity of their 
CD4 binding sites were further confirmed. 
 
The ability of recombinant gp120ZM651 to interact with CD4 was further corroborated in 
CD4 binding ELISA’s (Figure 3.6). Like 17b, 48D binds to a highly conserved region 
on HIV-1 gp120 that becomes more accessible following the gp120-CD4 interaction 
[283, 284]. Our results showed that in the presence of sCD4, 48D was unable to 
interact with gp120ZM651 as efficiently as it did with gp120BaL (Figure 3.6B and A, 
respectively). Comparably, 48D showed no binding activity against gp140AncC and 
HIV-196ZM651gp120 (Figure 3.6C and D, respectively). These results agree with a 
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previous finding that had demonstrated 48D binding to gp120BaL, but showed poor 
reactivity against subtype C isolates [283, 284]. Therefore, it is clear that 48D is not a 
suitable antibody for the characterization of recombinant subtype C Env 
glycoproteins.  
 
Since both 48D and 17b interact with CD4 induced epitopes, it has been suggested 
that these two antibodies share a common binding site [284]. It is possible that the 
amino acid residues required for a successful 48D-gp120 binding are similar, or 
overlap with those in the 17b-gp120 interaction. Well conserved gp120 regions, such 
as the ring structure linking the C3 and C4 regions, the base of the stem loop 
structure in the V1 and V2 loops, a ten amino acid sequence in the C2 region and the 
C5 region, have been implicated in 17b and 48D binding [284]. In addition, most of 
the gp120 residues implicated in 17b and 48D binding are hydrophobic [284], 
providing a potential explanation for the restricted accessibility of their epitopes prior 
to the gp120-CD4 interaction [284].  
 
As expected, 2G12 showed a high affinity for gp120BaL but bound poorly to gp120ZM651 
and gp140AncC (Figures 3.5A, B and C). MAb 2G12 recognizes a cluster of high 
mannose sugars composed of external α 1-2 terminal mannose residues on gp120 
[285, 286].  Mutational studies have demonstrated the importance of N-linked glycans 
at positions 295, 332 and 392 on gp120 in 2G12 binding [285-287]. A probable 
explanation for the poor binding activity of 2G12 to gp120ZM651 and gp140AncC is that 
subtype C Env glycoproteins often lack the Asparagine residue at glycosylation site 
295, and contain a valine residue instead [276, 288, 289]. More recently, it was 
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shown that glycosylation site 295 is not the sole determinant of 2G12 binding 
resistance and that glycosylation sites, 442 and 448 play a major role in the binding of 
2G12 to subtype C viruses [287].  The ability of 2G12 to bind gp120BaL confirms that it 
is properly folded and glycosylated, while its inability to bind gp120ZM651 and 
gp140AncC suggests differences in the structure and pattern of glycosylation between 
recombinant subtype B and C Env glycoproteins.   
 
The initial Annexin V and 7-AAD staining protocol was used for the analysis of 50nM, 
250nM and 500nM soluble recombinant gp120BaL and gp120ZM651-mediated apoptosis 
and showed low levels of early and late apoptosis of uninfected Jurkat T lymphocytes. 
In addition, a dose dependent response effect on the levels of late apoptosis was not 
observed in the Jurkat T lymphocytes when treated with 250nM and 500nM 
recombinant gp120BaL and gp120ZM651 post 48 hours (Table 3.1), as shown previously 
by Ullrich et al. (2000) in human umbilical vein endothelial cells using X4 gp120 and 
gp160 and by Hesselgesser et al. (1998) in Human hNT neurons in the absence of 
CD4 and through co-receptor signalling [237, 247].  
 
Ullrich et al. (2000) utilized gp120 and gp160 at concentrations of 0.1µg/ml and 1 
µg/ml and observed a dose dependent response at 10 hours post treatment through 
gp120-CXCR4 signalling [237]. Therefore, it is possible that complete saturation of 
the CD4 receptors with recombinant gp120BaL and gp120ZM651 Env glycoproteins at 
concentrations of 30µg/ml (250nM) and 60µg/ml (500nM) after 24 and 48 hours of 
exposure, could have contributed to the lack of a dose dependent response observed 
in our study. Soluble gp120 concentrations within the lymph nodes of HIV-1 infected 
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patients reportedly range between 120-960ng/ml (~1nM-8nM) [290, 291] while the 
concentrations of gp120 within the serum of HIV-1 infected patients reportedly range 
from 12-92ng/ml (~0.1nM-0.76nM) [292]. Ideally, future work should investigate the 
apoptotic ability of a range of lower soluble Env glycoprotein concentrations that are 
similar to those reported in HIV-1 infected individuals. Furthermore, there seems to be 
a concentration effect of 50nM, 250nM and 500nM gp120BaL and gp120ZM651 on early 
apoptosis of Jurkat T lymphocytes post 48 hours (Table 3.1). Forthcoming 
experiments should monitor apoptosis for more than 48 hours to determine if an 
optimal dose response effect can be attained.     
 
Nevertheless, a higher level of early apoptosis and a lower level of late apoptosis was 
observed in the 250nM (7.4% early; 2.2% late) and 500nM (9.3% early; 2.5% late) 
gp120BaL-treated Jurkat T lymphocytes in comparison to that of the 50nM gp120BaL 
(0.4% early; 6.9% late) treatment at 48 hours post exposure. A similar effect was 
observed in the gp120ZM651-treated Jurkat T lymphocytes i.e. demonstrated a higher 
level of late apoptosis after 48 hours of exposure to 50nM gp120ZM651 in comparison 
to the higher concentrations used (Table 3.1). This may be attributed to a dose 
dependent apoptotic response seen between the 50nM, 250nM and 500nM gp120BaL 
and gp120ZM651 concentrations. A large proportion of the susceptible Jurkat T 
lymphocytes treated with the 250nM and 500nM concentrations of gp120BaL and 
gp120ZM651 may have already undergone late apoptosis and necrosis at 48 hours post 
treatment (no staining), hence the detection of lower levels of late apoptosis. Future 
work could determine whether there is an Env-mediated dose dependent apoptotic 
response in Jurkat T lymphocytes by monitoring apoptosis more frequently, and for a 
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longer time period. In addition, the impact of ongoing Jurkat T lymphocyte cell division 
should be elucidated.  
 
Using the modified protocol, higher levels of early than late apoptosis were observed 
after 48 hours of exposure to 50nM gp120BaL, gp120ZM651 and gp140AncC (Table 3.2 
and Figure 3.12).  Furthermore, there were higher levels of late apoptosis observed 
after 24 hours of exposure compared to those observed at 48 hours post treatment of 
all three Env glycoproteins. This phenomenon could be attributed to Jurkat T 
lymphocytes ‘recovering’ from late apoptosis. The apoptotic signalling via a gp120-
CD4 interaction seems to be weak and consequently reversible as some Jurkat T 
lymphocytes were able to recover from late apoptotic events (Table 3.2 and Figure 
3.12). It is likely that early apoptotic events are reversible as well, however that was 
not observed in this study or to our knowledge in previous studies of this type, and 
therefore cannot be confirmed.  The weak signalling could be attributed to unstable 
interactions formed between gp120BaL, gp120ZM651 and gp140AncC and the CD4 
receptor causing the recombinant Env glycoproteins to attach and then detach shortly 
thereafter. As a result, the apoptotic signals transduced were possibly incomplete or 
partially lost along the pathway resulting in the low levels of early and late apoptosis 
that were observed. 
 
Since Jurkat T lymphocytes express CD4 receptors only, the apoptosis levels 
observed are presumably due to signalling cascades initiated solely by the interaction 
of recombinant gp120BaL, gp120ZM651 and gp140AncC with CD4.  Apoptotic signalling 
via gp120-CD4 interactions has been reported previously in PBMCs and CD4+ T 
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lymphocytes [227, 231, 293]. Since CD4 is associated with p56Lck, a T lymphocyte 
specific tyrosine kinase (also expressed in Jurkat and CEM T lymphocytes) [294], its 
involvement in CD4 signalling has been suggested [61, 295]. The cross linking of 
CD4 with gp120 reportedly upregulates CD4 associated p56Lck kinase activity which 
then decreases over long periods of time [296]. Decreased p56Lck activity is 
characterised by the dissociation of p56Lck from the CD4 receptor which can be 
caused by the interaction of gp120 with CD4 [296, 297].  
 
Ultimately, several differences in the levels of apoptosis obtained after 48 hours of 
50nM gp120BaL and gp120ZM651 treatment were observed between the initial and 
modified flow cytometric protocols. Firstly, using the modified flow protocol, 50nM 
gp120BaL demonstrated similar levels of late apoptosis compared to those obtained 
using the initial flow protocol by 250nM and 500nM gp120BaL at 48 hours post 
treatment (Table 3.1 and 3.2 or Figure 3.12). Furthermore, using the initial protocol, 
50nM gp120BaL induced higher levels of late apoptosis (6.9%) at 48 hours post 
treatment (Table 3.1 and 3.2 or Figure 3.12). In contrast, using the modified protocol, 
50nM gp120ZM651 was able to induce higher levels of early and late apoptosis 
compared to all three concentrations of gp120ZM651 tested using the initial protocol 
(Table 3.1 and 3.2 or Figure 3.12). The introduction of the gating strategy used in the 
modified protocol may be responsible for these differences; however, the results 
obtained from the modified protocol are probably more reliable since the population of 
Jurkat T lymphocytes analysed was confirmed to be CD4 positive, suggesting that 
any levels of apoptosis detected were mediated via CD4 (Figure 3.9B).        
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In a similar study conducted by Wang et al. (2009), through lactate dehydrogenase 
(LDH) assays, 10nM recombinant IIIB gp120 was shown to significantly reduce the 
viability of non-activated Jurkat T lymphocytes after 24 and 48 hours of treatment 
[298]. To further verify that the reduction in cell viability was a product of pro-apoptotic 
signals, the active form of caspase 3, DISC formation as well as Bax expression were 
successfully detected within the gp120-treated Jurkat T lymphocytes after just 24, 6 
and 3 hours, respectively [298]. In this study, the detection of DNA fragmentation by 
TUNEL analysis of the treated Jurkat T lymphocytes further validated that soluble 
recombinant gp120BaL, gp120ZM651 and gp140AncC were able to successfully induce 
low levels of apoptosis via CD4 signalling only (Figure 3.13). 
 
Apoptosis induced by gp120 can also be analysed by utilizing a model in which gp120 
is cross-linked with an anti-gp120 antibody and exposed to an anti-CD3 antibody 
[235, 299]. Using this model, Anand and Ganju, (2006) demonstrated gp120-
mediated DNA fragmentation, indicative of apoptosis in Jurkat T lymphocytes via 
TUNEL analysis [235]. Furthermore, gp120-mediated apoptosis was analysed in the 
presence and absence of anti-CD3 and anti-gp120 antibodies, demonstrating ~5% 
apoptosis of Jurkat T lymphocytes treated with only gp120 and a five-fold increase in 
the percentage of apoptosis of the Jurkat T lymphocytes treated with gp120, anti-
gp120 and anti-CD3 [235]. The percentage of apoptosis obtained when treated with 
gp120 only, agrees with those obtained in our study (Table 3.2 and Figures 3.12 and 
3.13). However, since immune activation has been suggested in the regulation of 
HIV-1-mediated apoptosis [235], the model of cross-linking gp120 better simulates 
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the in vivo situation in HIV-1 infected individuals and should be further evaluated in 
future Env-mediated apoptosis studies.    
 
The details of the binding kinetics between gp120, CD4 and co-receptors are not well 
understood. However, through single molecule analysis, Chang et al. (2005) were 
able to directly analyse the binding kinetics of a single gp120 molecule to single CD4 
and CCR5 molecules [300]. In agreement with the possibility that gp120BaL, 
gp120ZM651 and gp140AncC form weak or unstable interactions with CD4, it was shown 
that the gp120-CD4 interaction is of a low strength, short-lived and unless CCR5 (or 
CXCR4 in the case of X4 isolates) is within close proximity to CD4, gp120 will detach 
rapidly from CD4 [300]. It was further suggested that gp120 prepares to form a bond 
with its co-receptor soon after it forms a bond with CD4 [300]. Additionally, the force 
required to break the gp120-co-receptor interaction is supposedly larger than that 
required to break the gp120-CD4 interaction [300].  
 
Interestingly, it has been suggested that if the relevant co-receptor is not within close 
proximity of the CD4 receptor, gp120 presumably scans the cell membrane for a co-
receptor during the short-lived gp120-CD4 interaction [301]. However, previous 
studies have shown that gp120 induces the actin-dependent co-localization of CD4 
and its specific co-receptor during entry [302]. Once gp120 interacts with its co-
receptor, it is unclear if it remains bound to CD4 [301]. Since CCR5 is absent on the 
Jurkat T lymphocytes, it is possible that the CCR5-utilizing gp120BaL, gp120ZM651 and 
gp140AncC remained bound to the CD4 receptors for a short and limited period of time, 
resulting in low levels of apoptosis and recovery of lymphocytes due to weak or short-
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lived CD4 signalling. Similarly and more recently, Dobrowsky et al. (2008) proposed 
that the destabilization of the gp120-CD4 interaction over time and advancement to 
co-receptor interactions could be a viral mechanism that ensures efficient fusion and 
entry into the host cell [301].  
 
CD4 has been shown to be expressed as monomers and covalently linked 
homodimers on T lymphocytes, monocytes and macrophages, with the monomeric 
form prevailing on monocytes and lymphocytes [303, 304]. The organization of CD4 
and co-receptors on the lymphocyte surface appears to play a significant role during 
Env-mediated apoptosis, and this may vary with cell types [305]. Therefore, in 
addition to a short-lived gp120-CD4 interaction in the absence of a co-receptor, the 
organization of CD4 receptor molecules on the Jurkat T lymphocytes could be a 
contributing factor to the low levels of apoptosis that were detected.     
    
In comparison to the non-activated Jurkat T lymphocytes, higher levels of apoptosis 
were observed in the 50nM soluble recombinant gp120BaL, gp120ZM651 and gp140AncC-
treated, activated and uninfected CD4+ T lymphocytes (Table 3.3 and Figures 3.18). 
Contrary to several other findings which demonstrated soluble recombinant  CCR5-
utilizing gp120-mediated apoptosis after 5 [227] and 16 hours in PBMCs [239] and 6 
hours and 10 hours in HUVEC cells [237], insignificant levels of apoptosis of CD4+ T 
lymphocytes were observed after 5 hours of exposure to 50nM gp120BaL (data not 
shown). Consequently, 50nM gp120BaL, gp120ZM651 and gp140AncC-mediated 
apoptosis of CD4+ T lymphocytes was analysed at 24 and 48 hours post treatment. 
The levels of apoptosis observed in our study agree with previous findings that 
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demonstrate 10-15% of apoptosis mediated by gp120 [220, 231]. Roggero et al. 
(2001) observed similar levels of apoptosis even though gp120 was presented in a 
membrane-bound form, suggesting that soluble and membrane-bound Env 
glycoproteins are able to induce similar levels of apoptosis. Arthos et al. (2002) 
demonstrated approximately 4% and 7% apoptosis of 50nM R5 gp120-treated 
activated PBMCs via Annexin V/propidium iodide staining (post 5 hours) and TUNEL 
analysis (post 65 hours), respectively [227]. These apoptotic percentages are slightly 
lower than those obtained in our study; however it is possible that if a longer 
incubation period was allowed, the levels of apoptosis obtained would have been 
similar to ours. As observed previously and in our study, incubation times of 24 hours 
or more with soluble recombinant gp120 appear to be required to achieve low levels 
of bystander apoptosis [229].  
 
Since the CD4+ T lymphocytes express CD4 and co-receptor molecules, the 
apoptotic signalling observed could be attributed to both gp120-CD4 and gp120-
CCR5 signalling. Only a few primary CD4+ T lymphocytes express detectable levels 
of CCR5 [306, 307], however in support of the present study, R5 viruses have been 
shown to induce a significant decline in infected and uninfected CD4+ T lymphocytes 
via apoptosis by inducing expression of Fas and caspase 8 [224, 263, 306, 308].   
 
Differences between the Jurkat and CD4+ T lymphocytes that explain the variable 
results obtained could possibly include activation states and the presence of a co-
receptor on the cell surface. Kinet et al. (2002) demonstrated the importance of the 
activation state of CD4+ T lymphocytes in gp120-mediated signalling via CD4 and co-
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receptors CXCR4 or CCR5 [309]. The mitogen-activated protein kinase (MAPK) 
pathway was shown to be activated by gp120 in CD4+ T lymphocytes that had been 
activated via their T-cell receptors (TCR) via CD4 and co-receptors, and this was not 
observed in non-stimulated T lymphocytes [309]. Furthermore, gp120 has been 
shown to activate the MAPK pathway in activated CD4+ Jurkat T lymphocytes [309, 
310].  
 
Since the CD4+ T lymphocytes used in the current study were activated with PHA 
and pre-stimulated with hIL-2 before treatment with recombinant gp120BaL, gp120ZM651 
and gp140AncC, they were in a highly activated state. Therefore, the heightened state 
of immune activation is probably associated with the higher levels of apoptosis 
observed and the presence of co-receptors on the activated CD4+ T lymphocytes 
possibly provides additional apoptotic signals through gp120 interactions. Because 
different levels of PHA activation could impact on results obtained, this should be 
addressed in future studies. In addition, future work including the analysis of the 
contribution of the CCR5 co-receptor in subtype C R5 gp120-mediated apoptosis 
would be beneficial. These studies could be conducted in the presence and absence 
of the CCR5 inhibitor, TAK-779 [311] or by using CD4+ T lymphocytes that do not 
express CCR5 [312].   Dissecting out the important steps that follow gp120-CD4 and 
gp120-CCR5 interactions would assist in understanding the processes involved in the 
culmination of apoptotic signals that are activated by these interactions on CD4+ T 
lymphocytes. 
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The role of the CD4 receptor and co-receptors CCR5 and CXCR4 in Env-mediated 
apoptosis of activated PBMCs have been investigated previously. Arthos et al. (2002) 
confirmed that the Env-CD4 interaction is able to induce significant levels of apoptosis 
in the absence of a co-receptor [227]. Moreover, the levels of apoptosis were 
enhanced in the presence of co-receptors with X4 gp120 inducing higher levels of 
apoptosis than the R5 gp120 [227].  
 
Interestingly, analogous signalling cascades appear to be initiated by gp120 and the 
natural ligands for CXCR4 and CCR5 upon binding [310, 313]. The interaction of HIV-
1 gp120 with CCR5 on macrophages seems to activate ion channels for the transport 
of K+, Cl- and Ca2+ resulting in elevated levels of intracellular Ca2+ [232]. In addition, 
there have been implications for the involvement of CXCR4 in the induction of CD95-
independent apoptosis in CD4+ T cells [314]. Evidently, important signals are 
transduced after the interaction of HIV-1 gp120 with CCR5/CXCR4.  
 
The ability of monomeric gp120BaL and gp120ZM651 and trimeric/oligomeric gp140AncC 
to induce apoptosis was compared in the Jurkat T lymphocytes and CD4+ T 
lymphocytes. Annexin V/7-AAD staining (analysed using the modified flow cytometric 
protocol) and TUNEL analysis revealed that the levels of Jurkat T lymphocyte 
apoptosis induced by trimeric/oligomeric gp140AncC were similar to those induced by 
monomeric gp120BaL and gp120ZM651. Furthermore, the levels of apoptosis induced 
were very similar between the subtype B and C Env glycoproteins. These findings 
agree with those of Machuca et al. (2004) who showed inconsequential differences in 
the degree of apoptosis of PBMCs and CEM.NKR-CCR5 cells induced between 
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several HIV-1 group M viral isolates [315]. This suggests that recombinant R5 
monomeric gp120BaL, monomeric gp120ZM651 and trimeric/oligomeric gp140AncC were 
able to induce similar levels of apoptosis in Jurkat T lymphocytes in a conformation 
and subtype independent manner. Similarly, Zhang et al. (2001) reported comparable 
affinities between trimeric and monomeric HIV-1 gp140 for sCD4 [316] while, Bardi et 
al. (2006) demonstrated comparable levels of apoptosis of human neuroblastoma 
cells and mouse pre-B 300-19 cells, induced between monomeric and oligomeric IIIB 
gp120 even in the absence of CD4 [317].  
 
It can therefore be suggested that monomeric and oligomeric Env glycoproteins are 
able to induce comparable levels of apoptosis in Jurkat T lymphocytes, human 
neuroblastoma cells and mouse pre-B 300-19 cells. It is worth noting that subtype B 
gp120 demonstrated higher levels of apoptosis compared to subtype C gp120 during 
the Annexin V/7-AAD analysis using the initial flow cytometric protocol (Table 3.1). 
Because of our contrasting findings regarding the differences in apoptosis based on 
different Env glycoprotein subtypes, further investigation is required to confirm 
whether there is a significant difference in apoptosis induced between subtype B and 
C Env glycoproteins.   
 
A huge difference in the degree of apoptosis induced between the subtype B and C 
Env glycoproteins was not observed during the Annexin V/7-AAD and TUNEL 
analyses of the treated CD4+ T lymphocytes, but rather between the different forms 
i.e. monomeric versus oligomeric. During the Annexin V/7-AAD analysis, the 
oligomeric gp140AncC at a concentration of 50nM seemed to induce higher levels of 
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apoptosis in comparison to monomeric gp120BaL and gp120ZM651 (Figure 3.18), while 
during the TUNEL analysis, gp120ZM651 induced higher levels of DNA fragmentation in 
comparison to gp120BaL and gp140AncC (Figure 3.20). Moreover, when used at a 
concentration of 100nM, slight variations in the levels of apoptosis induced by all 
three Env glycoproteins was observed. Interestingly, and similarly to Arthos et al. 
(2002) who utilized X4 gp120 (HIV-1 92UG21-9) [227], an increase in the levels of 
apoptosis was not observed when CD4+ T lymphocytes were treated with 100nM 
gp120BaL, gp120ZM651 and gp140AncC (Figure 3.19). However, a dose dependent effect 
of gp120 on apoptosis has been observed previously in CD4+ [251, 299] and CD8+ T 
lymphocytes [318]. Different forms of gp120 (monomeric, trimeric and oligomeric) 
exist in an infected individual, possibly in varying proportions; however the 
concentrations of each in vivo are unclear and would vary with patients’ viral loads.   
 
Since our experiments were performed using CD4+ T lymphocytes from different 
donors, the discrepancies in the results obtained could be due to donor variability or 
the different methodologies used. For example, Accornero et al. (1997) used the 
model in which the CD4+ T lymphocytes were treated with gp120 cross-linked with 
anti-gp120 and anti-CD3 antibodies [299]. Since slight variations in the levels of 
apoptosis induced by 50nM and 100nM monomeric gp120BaL and gp120ZM651 and 
trimeric/oligomeric gp140AncC were observed during both the Annexin V/7-AAD 
(Figure 3.18 and 3.19) and TUNEL analyses (Figure 3.20), the difference in apoptosis 
induced between monomeric and trimeric/oligomeric Env glycoproteins is unclear and 
additional studies are required to clarify whether a difference may exist. Furthermore, 
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forthcoming experiments should employ a single donor to limit any inconsistencies 
due to donor variation. 
     
In a recent study, HIV-1 subtype C Vpr was found to induce lower levels of apoptosis 
of 293T cells in comparison to subtype B Vpr [319]. Presumably, the effect of other 
pro-apoptotic HIV-1 proteins on the level of apoptosis induced may vary between 
subtypes. Moreover, differences in apoptosis induced by different HIV-1 subtypes 
during HIV-1 infection are possibly influenced by a collective contribution from each 
pro-apoptotic HIV-1 protein.      
   
An interesting observation during both the Annexin V/7-AAD and TUNEL analysis of 
the recombinant R5 gp120BaL, gp120ZM651 and gp140AncC-treated CD4+ T 
lymphocytes,  was the shifting of the CD4+ CD3+ lymphocyte population into the 
CD4-CD3+ quadrant after just 24 hours of exposure (Figure 3.15). The inability of the 
CD4-PE antibody to stain the lymphocytes could be because gp120BaL, gp120ZM651 
and gp140AncC have remained bound to the CD4 receptors. If this is the case, then it 
can be suggested that the CD4-PE antibody gp120BaL, gp120ZM651 and gp140AncC 
share a common binding site. Another explanation for this phenomenon could be the 
down regulation of CD4 receptors post Env glycoprotein treatment. Long and short 
term exposure of CEM cells to gp120 has been investigated previously by Juszczak 
et al. (1991), demonstrating that 20 hours of gp120 exposure resulted in a 35% 
decrease of cell surface expressed CD4 [296]. Moreover, the down regulation of CD4 
receptors occurs subsequent to the dissociation of CD4-p56Lck complex which is 
thought to be caused by gp120 binding [296]. This phenomenon was not observed in 
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the recombinant gp120BaL, gp120ZM651 and gp140AncC-treated Jurkat T lymphocytes, 
possibly due to the absence of the CCR5 co-receptor which reportedly establishes a 
stronger interaction with gp120 post CD4 receptor binding. This interesting 
observation warrants further investigation into the expression levels of CD4 molecules 
on the surface of Jurkat and CD4+ T lymphocytes.   
 
During the course of HIV-1 infection, CCR5-utilizing viruses switch to CXCR4-utilizing 
viruses which in turn correlates with the progression to AIDS which is defined by a 
progressive decline in CD4+ T lymphocytes [76]. Therefore, since apoptosis is one of 
the main contributors to CD4+ T lymphocyte depletion, it can be hypothesized that R5 
gp120 induces low levels of apoptosis throughout the course of HIV-1 infection, 
however, upon increased incidence of X4 gp120, the levels of apoptosis intensify.  
Furthermore, R5 viruses are preferentially transmitted; therefore, intense rates of 
apoptosis induced by these viruses would not be beneficial for their survival.  
Previously, it was shown that both X4 and R5 viruses are very similar in terms of 
active viral replication and cytopathicity, however, X4 viruses tend to induce a more 
rapid decline in CD4+ T lymphocytes due to the fact that CXCR4 is expressed more 
extensively than CCR5 [320, 321].  
 
Overall, the levels of apoptosis seen in this study are not extremely high but probably 
correlate with those occurring in typical progressor patients i.e. a gradual turnover of 
CD4+ T lymphocytes and depletion over approximately 10 years. Apoptosis of 
immune cells during the early stages of in HIV-1 infection is believed to be involved in 
the disruption of the anti-HIV immune response which ultimately affects disease 
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progression [322]. To assist in understanding the role of Env-mediated-apoptosis in 
disease progression, it would be beneficial to evaluate and compare the difference in 
the levels of apoptosis induced between subtype C R5 and X4-utilizing Env 
glycoproteins relative to the different stages of HIV-1 infection. These studies could 
be conducted in vitro, through the comparison of subtype C R5 and X4 Env 
glycoprotein induced apoptosis of PBMC’s from HIV-1, subtype C positive donors at 
different clinical stages of infection.  
 
In summary, the present study demonstrated that recombinant gp120BaL, gp120ZM651 
and gp140AncC were able to induce pro-apoptotic signals in uninfected Jurkat T 
lymphocytes as well as in uninfected activated CD4+ T lymphocytes. Apoptotic 
signalling in the Jurkat T lymphocytes can be attributed to signalling via the CD4 
receptor, while the apoptotic signalling in the CD4+ T lymphocytes were likely 
transduced via CD4 and co-receptor engagement, potentially with additional 
contributing signals from the activated TCR. Elucidating the apoptotic events induced 
by HIV-1 gp120 could assist in understanding HIV-1 disease progression and CD4+ T 
lymphocyte depletion in AIDS patients and could lead to novel therapeutic strategies 
and antiretroviral drug discoveries. Therapeutic developments that could possibly 
block or inhibit apoptotic signal transduction at early or late stages of the pathway 
could drastically affect patient outcomes and CD4+ T lymphocyte counts.  
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APPENDIX A: Laboratory Recipes 
 
A.1 Solutions for bacterial cell culture, production of competent E. coli DH5α 
cells and transformation of competent E. coli DH5α cells 
 
Luria-Bertani (LB) Broth 
10g of tryptone powder (Oxoid, Hampshire, England), 5g of yeast extract powder 
(Biolab, Wadeville, Gauteng, South Africa) and 5g of NaCl (Sigma-Aldrich, Steinheim, 
Germany) was dissolved in sH2O (Dismed Criticare, Midrand, South Africa) and made 
up to a final volume of 1L. The broth was autoclaved (121ºC, 20 minutes) and stored 
at room temperature until use. 
 
LB Agar plates 
3g of agar powder (Biolab, Wadeville, Gauteng, South Africa) was dissolved in 200ml 
of LB broth. The agar was autoclaved and cooled before the ampicillin (100µg/ml) 
(Roche, Mannheim, Germany) was added (Ex: 200ml of broth or agar = 200µl 
ampicillin). Thereafter, the agar was poured into 90mm Petri dishes under sterile 
conditions and allowed to set at room temperature. 
 
70% (v/v) Ethanol (1L) 
1.4L >99.9% Ethanol (Merck, Hohenbrunn, Germany) was made up to a final volume 
of 2L with sH2O (Dismed Criticare). 
 
Ampicillin (100mg/ml) 
1g Ampicillin (Roche) was dissolved in 10ml of 70% Ethanol (Merck). The stock 
solutions were stored at -20oC in 1ml aliquots until required. 
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Transformation Buffer (100mM CaCl2, 10mM PIPES-HCl, 15% Glycerol, pH 7.0) 
1.4702 g of CaCl2.2H2O (Sigma-Aldrich, Steinheim, Germany), 0.3024 g of PIPES 
(Boehringer Mannheim, GmbH, Germany) and 15ml of glycerol (Merck, Hohenbrunn, 
Germany) were made up to a final volume of 100 ml with sH20 (Dismed Criticare).  
The pH of the solution was adjusted to 7.0 using 10M NaOH (Merck, Darmstadt, 
Germany), and the buffer was autoclaved and stored at -20 ºC until use. 
 
A.1.2 Isolation of plasmid DNA (Protocol obtained from the QIAfilter Plasmid 
Purification Handbook, Qiagen) 
All buffers were provided in the Qiagen QIAfilterTM Plasmid Maxi Kit (Qiagen, 
Maryland, USA). 
 
Composition of Resuspension Buffer P1 (50mM Tris-Cl, 10mM EDTA, 100µg/ml 
RNase A)  
6.06g of Tris base powder  
3.72g Na2EDTA.2H2O  
The pH of the solution was adjusted to 8.0 with HCl before being made up to a final 
volume of 1L with sH2O. For every litre of P1 buffer, 100mg of RNase A was added. 
Stored at 4ºC after the addition of RNase A. 
Composition of Lysis Buffer P2 (200mM NaOH, 1% SDS) 
8.0g NaOH pellets 
50ml of 20% Sodium Dodecyl Sulphate (SDS) (w/v) solution 
Made up to 1L in sH2O and stored at room temperature 
Composition of Neutralization Buffer P3 (3.0M Potassium acetate) 
294.5g Potassium Acetate 
The pH was adjusted to 5.5 with glacial acetic acid before the final volume was 
adjusted to 1L with sH2O. This solution was stored at room temperature. 
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Composition of Buffer QBT ((750mM NaCl, 50mM MOPS, 15% isopropanol, 
0.15% Triton X-100) 
43.83g NaCl 
10.46g MOPS (free acid) 
The pH was adjusted to 7.0 with NaOH before 150ml of pure isopropanol and 15ml of 
10% Triton X-100 solution (v/v) was added. The final volume was adjusted to 1L with 
sH2O and stored at room temperature. 
Composition of Buffer QC (1.0M NaCl, 50mM MOPS, 15% isopropanol) 
58.44g NaCl  
10.46g MOPS (free acid) 
The pH was adjusted to 7.0 with NaOH before 150ml of pure isopropanol was added. 
The final volume was adjusted to 1L with sH2O and stored at room temperature. 
Composition of Buffer QF (1.25M NaCl, 50mM Tris-Cl, 15% isopropanol) 
73.05g NaCl 
6.06g Tris base powder 
The pH was adjusted to 8.5 with HCl before 150ml of pure isopropanol was added. 
The final volume was adjusted to 1L with sH2O and stored at room temperature. 
 
A.1.3 Agarose Gel Electrophoresis 
 
 0.5M Ethylenediamine tetraacetic acid (EDTA) (pH 8.0) 
93.05 g of EDTA powder (Calbiochem, CA, USA) was dissolved in sH20 (Dismed 
Criticare) to a final volume of 500 ml. The pH of the solution was adjusted to 8.0 using 
10M NaOH and subsequently autoclaved and stored at room temperature until use. 
The EDTA was only soluble once the pH had reached 8.0.  
 
50X Tris Acetate EDTA (TAE) Buffer 
242 g of Tris (hydroxymethyl)-aminoethane (Sigma-Aldrich, Steinheim, Germany), 
57.1 ml of glacial acetic acid (Merck, Hohenbrunn, Germany) and 100 ml of 0.5 M 
EDTA (Calbiochem) were mixed with sH20 (Dismed Criticare) to a final volume of 1 L 
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and stored at room temperature until use.  Immediately before use, the solution was 
diluted to 1X TAE by mixing 20ml of 50X TAE with 980ml of sH20 (Dismed Criticare). 
 
6X DNA Loading Buffer 
0.25% Bromophenol Blue (Merck Chemicals, Saarchem, Wadeville, South Africa) and 
30% glycerol (Merck) was made up in 10ml of sH2O (Dismed Criticare). The buffer 
was stored in 1ml aliquots at -20oC until required. 
 
0.8% Agarose gel 
0.8g of agarose powder (Sigma-Aldrich, Steinheim, Germany) was added to 100ml of 
1X TAE buffer and heated until the agarose powder had dissolved completely. The 
agarose solution was cooled slightly before 7.5µl of Ethidium Bromide (Promega 
Corporation, Madison, USA) was added to it (used at a concentration of 0.5μg/ml). 
Finally the solution was poured into a Bio-Rad Gel Chamber System (Bio-Rad, 
Hercules, CA) and allowed to set. 
 
A.2 Mammalian Cell culture 
 
Complete culture media 
50ml Heat-inactivated (56oC water bath for 30 min) Fetal Calf Serum/Bovine serum 
(Gibco; Grand Island, USA), 5ml 200mM 100X stock L-glutamine (Gibco; Grand 
Island, USA), 2.5ml 10000µg/ml Penicillin-Streptomycin (Gibco; Grand Island, USA) 
was added to 500ml RPMI 1640 without L-glutamine (Sigma-Aldrich; Steinheim, 
Germany) in the case of Jurkat T lymphocytes and CD4+ T lymphocytes or 500ml 
DMEM (Sigma-Aldrich; Steinheim, Germany) in the case of HEK 293T cells. 
 
Freezing Mix 
50% of heat-inactivated FCS, 40% RPMI/DMEM and 10% filter sterilized (0.2 μM 
Acrodisc® 25 mm syringe filters; Pall Corporation, Ann Arbor, MI, USA) Dimethyl-
sulphoxide (DMSO) ((Fluka Biochemika, Steinheim, Germany) was made up to the 
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volume required and 1ml of the freezing mix was added per 1x106 cells. The freezing 
stocks were aliquoted in 1 ml quantities into autoclaved cryovials (Nunc, Roskilde, 
Denmark) and stored in a nest box overnight at -80ºC, and moved into liquid nitrogen 
storage until required.  
 
A2.1 Solutions for Calcium Chloride (CaCl2) transfections 
 
2.5M CaCl2  
91,85g CaCl2.H2O (Sigma-Aldrich) was dissolved in sH2O (Dismed Criticare) to a final 
volume of 250ml. The solution was filter sterilized using 0.2 μM Acrodisc® 25 mm 
syringe filters (Pall Corporation) and stored at -20oC in 10ml aliquots until required. 
 
2x HEPES (280mM NaCl, 50mM Hepes, 1.5mM Na2HPO4.2H2O) 
0.817g NaCl (Sigma-Aldrich), 0.6g Hepes (Sigma-Aldrich, Steinheim, Germany) and 
0.013g Na2HPO4.2H2O (Sigma-Aldrich, Steinheim, Germany) was dissolved in sH2O 
to a final volume of 50ml. The pH was adjusted to 7.7 using 10M NaOH and the 
solution was filter sterilized and stored in 5ml aliquots at -20oC until required.  
 
A2.2 Solutions for Protein Purification 
 
1M NaCl in 1X PBS 
29.22g of NaCl (Sigma-Aldrich) was dissolved in ice-cold 1X Dulbecco’s Phosphate 
Buffered Saline (without CaCl2) (PBS) (Sigma-Aldrich, Steinheim, Germany) to a final 
volume of 500ml. This solution was stored at 4ºC until required. 
 
0.75M Methyl α-D-mannopyranoside (MMP) 
7.4g of MMP (Sigma-Aldrich, Steinheim, Germany) was dissolved in ice-cold 1X PBS 
to a final volume of 50ml. This solution was prepared fresh every time before 
required. 
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0.01% Sodium Azide 
0.01g of Sodium Azide (extremely neurotoxic) (Sigma-Aldrich, Steinheim, Germany) 
was weighed out in a fume hood and dissolved in 100ml of sH20. This solution was 
stored at room temperature until required. 
 
BSA Protein Assay Kit (Thermo Scientific) 
Reagent A contains sodium carbonate, sodium bicarbonate, bicinchonic acid and 
sodium tartrate in 0.1M NaOH. 
Reagent B contains 4% cupric sulfate 
 
A.3 Solutions for SDS-PAGE 
 
10X Tank Buffer pH 8.3 
30.3g of Tris (hydroxymethyl)-aminoethane (Sigma-Aldrich, Steinheim, Germany), 
144.1g of Glycine (Merck, Darmstadt, Germany) and 10g of SDS (Merck, Darmstadt, 
Germany) was dissolved in 1000ml of sH20. The solution was diluted 10 times before 
use and stored at room temperature. 
 
4X Stacking Gel Buffer pH 6.8 
30.2g of 0.5M Tris was dissolved in 100ml of sH20. The pH was adjusted to 6.8 using 
1M HCl and the solution was made up to a final volume of 500ml and subsequently 
stored at 4oC until required  
 
4X Resolving Gel Buffer pH 8.8 
90.8g 1.5M Tris was dissolved in 100ml of sH20. The pH was adjusted to 8.8 using 
1M HCl and the solution was made up to a final volume of 500ml and subsequently 
stored at 4oC until required.  
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10% SDS 
10g of SDS (Merck) was dissolved in sH20 to a final volume of 100ml and stored at 
room temperature until required. 
 
10% Ammonium Persulphate (APS) 
0.1g of APS (Sigma-Aldrich, Steinheim, Germany) was dissolved in sH20 to a final 
volume of 1ml.  This solution was prepared fresh each time before use. 
 
8% Resolving Gels (2 gels) 
11.83ml of sH20, 6.25ml of the 4X Resolving gel buffer, 6.67ml of the Acrylamide/bis-
Acrylamide 30% Monomer solution (Sigma-Aldrich; Steinheim, Germany, Catalogue 
number: A3449) and 250μl of 10% SDS were mixed together and just before casting 
the gel solutions, 250μl of 10% APS and 15μl of Tetramethylethylene-diamine 
(TEMED) (Sigma-Aldrich; Steinheim, Germany) was added to the solution and gently 
mixed.  
 
Stacking Gel (2 gels) 
5.73ml of sH20, 2.5ml of the 4X Stacking gel buffer, 1.67ml of the Acrylamide/bis-
Acrylamide 30% Monomer solution and 100μl of 10% SDS were mixed together and 
just before casting the gel solutions, 100μl of 10% APS and 10μl of TEMED was 
added to the solution and gently mixed.  
 
2X Loading Buffer 
2.5ml of the 4X Stacking gel buffer, 4ml of 10% SDS, 2ml Glycerol (Merck, 
Darmstadt, Germany), 100µl β-mercaptoethanol (Sigma-Aldrich; Steinheim, 
Germany) and a 2mg of Bromophenol Blue (Saarchem) was dissolved in sH20 and 
made up to a final volume of 20ml. The solution was stored at -20ºC until required. 
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A.4 Solutions for Western Blotting 
 
Transfer Buffer pH 9.2 
200ml of methanol (Merck Chemicals, Saarchem, Wadeville, South Africa), 100 ml of 
10X Tank Buffer and 700ml of sH20 were mixed and stored at room temperature until 
required. 
 
10X Tris-Buffered Saline (TBS) (pH 7.4) 
160g of NaCl, 4g of KCl (Sigma-Aldrich; Steinheim, Germany) and 60g of Tris pH 8.0 
were dissolved in sH20 to a final volume of 2L. The pH was adjusted to 7.4 using HCl 
and the solution was then autoclaved and stored at room temperature until required. 
 
TBS containing 0.1% Tween-20 (T-TBS) 
The 10X TBS stock solution was diluted 1:10 times with sH20 and Tween 20 
(Saarchem, Midrand, South Africa) was added at a concentration of 0.1% (v/v). This 
solution was prepared fresh each time before use. 
 
5% Skimmed milk (Blocking Buffer)  
5g of Blotting Grade Blocker (non-fat dry milk) (Biorad, Hercules, CA) was dissolved 
on 100ml of T-TBS. This solution was prepared fresh each time before required. 
 
1X T-PBS containing 0.5% Bovine Serum Albumin (BSA) (T-PBS-BSA) 
0.5g of BSA was dissolved in 100ml of 1X T-PBS. This solution was prepared fresh 
each time before required. 
 
NBT/BCIP Solution 
A quarter of a NBT/BCIP tablet (Roche, Mannheim, Germany) was dissolved in 2.5ml 
of sH20 with minimal light exposure. This solution was prepared fresh each time 
before use.  
 
 135 
A.5 Solutions for Coomassie Staining 
 
Coomassie Blue Staining 
0.25g of Coomassie® Brilliant Blue R250 (Sigma-Aldrich; Steinheim, Germany) was 
dissolved in 500ml of methanol, 100ml of acetic acid and 400ml of sH20.  This 
solution was stored at room temperature until required. 
 
Destaining Solution 1 (40% Methanol, 7% Acetic Acid) 
400ml of methanol, 70ml of acetic acid (Merck, Darmstadt, Germany) and 530ml of 
sH20 were mixed and stored at room temperature until required. 
 
A.6 Solutions for ELISA’s 
 
2M Sulphuric Acid (H2SO4) 
54,3ml of H2SO4 (98% H2SO4; Molarity=18, 4) was mixed with 445.7ml of sH20 and 
stored at room temperature until required. 
 
1X PBS containing 0.05% Tween 20 (T-PBS) 
A solution of 10X PBS was diluted 1:10 times with sH20 and Tween-20 was added at 
a concentration of 0.05% (v/v). This solution was prepared fresh each time before 
required. 
 
1X T-PBS containing 10mg/ml Bovine Serum Albumin (BSA) (T-PBS-BSA) 
(Blocking Buffer)  
BSA (Roche; Mannheim, Germany) was mixed with 1X T-PBS at a concentration of 
10mg/ml. This solution was prepared fresh each time before required. 
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A.7 Solutions for the isolation of CD4+ T lymphocytes 
 
1X PBS containing 2% FCS (PBS-FCS) 
10ml of heat-inactivated FCS (Gibco; Grand Island, USA) was added to 500ml of 1X 
PBS and stored at 4ºC until required for use. 
 
A.8 Flow Cytometry Solutions 
 
Composition of 10X Binding Buffer (provided in the Annexin V/7-AAD kit) 
(Beckman Coulter, USA) 
0.1M Hepes pH 7.4, 1.4M NaCl and 25mM CaCl2 was dissolved in sH20 and stored at 
4ºC. This solution was diluted ten times with sH20 and stored at 4ºC until required for 
use. 
 
Camptothecin Stock Solution at 10mg/ml 
25mg of Camptothecin (Sigma-Aldrich; Steinheim, Germany) (weighed out in a fume 
hood as it is extremely toxic) was dissolved in 2.5ml of filter sterilized DMSO. The 
solution was stored in the dark at 4ºC and thawed in a 37ºC water bath before use. 
 
4µM Camptothecin 
0.14µl of the 10mg/ml stock solution was added to each 1ml culture of Jurkat T 
lymphocytes or CD4+ T lymphocytes.   
 
4% Paraformaldehyde (PFA) Stock Solution (10ml) 
4g of PFA (weighed out in a fume hood as it is extremely toxic) ((BDH Limited Poole, 
England) and 5µl of 1M NaOH was added to 8ml of sH20 before being heated for 10 
minutes at 59ºC while vigorously shaking. The volume of solution was adjusted to 9ml 
with sH20 followed by the addition of 1ml of 10X PBS. The solution was mixed and 
stored at -20ºC in 1ml aliquots for a maximum period of one month. Before use, the 
4% PFA stock solution was diluted 1:4 times in 1X PBS and used at room 
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temperature as 1% PFA. This solution was stored at 4ºC for a maximum period of a 
week. 
 
20mM EDTA 
4ml of 0.5M EDTA was added to 96ml of sH20 and stored at room temperature until 
required.  
 
1X PBS containing 0.1% Triton X-100 and 5mg/ml BSA (50ml) 
5µl of Triton X-100 (Merck, Darmstadt, Germany) and 0.25g of BSA was dissolved in 
50ml of 1X PBS. The solution was stored at 4ºC until required. 
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